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Introduction 
Motor neuron diseases (MNDs)  
Motor neuron diseases (MNDs) are a heterogeneous group of disorders characterized by death of 
motor neuron cells. MNDs occur in both adults and children.  In children, MNDs are usually 
characterized by familial forms of the disease; symptoms can be present at birth or appear before the 
child learns to walk.  In adults, MNDs occur more commonly in men than in women, with symptoms 
appearing generally after the age of 40 1. 
MNDs may be sporadic or familial and are clinically classified according to whether they involve upper 
or lower motor neurons, or both. Upper motor neuron involvement leads to positive neurological 
features including spasticity, brisk reflexes, clonus, and extensor plantar responses, as well as negative 
features such as weakness and loss. Spasticity is defined as the velocity-dependent increase in muscle 
tone as assessed by passive movement of the limbs. The term is used to define the stiffness and other 
features due to the damage of descending motor pathways in the central nervous system. This 
damage, frequently in the spinal cord, leads to abnormal hyper-excitability of the tonic stretch reflex. 
Consequently, the patient with spastic legs complains of walking difficulty, weakness, fatigue, and 
reduced exercise tolerance. They may also have cramps of the legs due to spontaneous clonus. Lower 
motor neuron loss, on the other hand, leads to muscle wasting with fasciculation, weakness, and 
reduced or abolished reflexes 1.  
 
Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease is a classical MND; it is a 
progressive fatal disorder that involve both upper and lower motor neurons. Symptoms usually 
appear first to the limbs, or swallowing muscles.   Affected patients lose strength and the ability to 
move their arms and legs, and to hold the body upright. ALS is also characterized by other symptoms 
such as spasticity, spasms, muscle cramps, and fasciculations. At end stage of the disease muscles of 
the diaphragm and chest fail to function properly and patients lose the ability to breath without 
mechanical support. Usually ALS patients die from respiratory failure, within three to five years from 
the onset of symptoms.  However, about 10 percent of affected individuals survive for ten or more 
years 2.  
Rarely ALS patient present symptoms that involve the person's personality, anyway some recent 
studies report evidence that some patient with ALS may develop cognitive problems involving word 
fluency, decision-making, and memory.   
ALS classical patient are people between 40 and 60 years of age, but also younger and older individuals 
can develop the disease.  It is also known that men have a higher incidence than women. Familial 
forms of ALS represent only the  10 percent or less of ALS cases, with more than ten genes identified 
to date.  2.  
 
Progressive bulbar palsy (PBP), also called progressive bulbar atrophy, involves the brain stem, which 
is the bulb-shaped region containing lower motor neurons needed for swallowing, speaking, chewing, 
and other functions. Limb weakness with both lower and upper motor neuron signs is almost always 
evident. Patients present symptoms include pharyngeal muscle weakness, weak jaw and facial 
muscles, progressive loss of speech, and tongue muscle atrophy. Moreover, PBS patient present high 
risk of choking, event that occurs when foods or liquids cross through the vocal folds reaching airways 
and lungs affected persons present also emotional lability such as unmotivated outbursts of laughing 
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or crying.  Stroke and myasthenia gravis may have certain symptoms that are like those of progressive 
bulbar palsy and must be ruled out prior to diagnosing this disorder 1.  
 
Pseudobulbar palsy, often confused with PBP because of many common, is characterized by 
degeneration of upper motor neurons that transmit signals to the lower motor neurons in the brain 
stem.  Patients are affected by progressive loss of the ability to speak, chew, and swallow.  Progressive 
weakness in facial muscles is also present leading to an expressionless face.  Individuals may develop 
a gravelly voice and an increased gag reflex.  The tongue may become static and unable to protrude 
from the mouth 3.  
 
Primary lateral sclerosis (PLS) affects only the upper motor neurons involving arms, legs, and 
face.  PLS depend on degeneration of one specific pool of nerve cells in the motor cortex, leading to 
slow and challenging movements.  The disorder often affects the legs first, then the body trunk, arms 
and hands, and, finally, the bulbar muscles. Also, speech ability may be involved becoming 
slow.  When affected, the legs and arms become inflexible, clumsy, slow and weak, leading to an 
inability to walk or carry out tasks requiring fine hand coordination.  Difficulty with balance may lead 
to falls.  Affected individuals commonly experience pseudobulbar symptoms and an overactive startle 
response. Generally, PLS occurs between ages 40 and 60, and like ALS also PLS is more common in 
men than in women, the cause is unknown ad the progression very slow, leading to progressive 
stiffness and clumsiness of the affected muscles.  PLS is usually considered a variant of ALS but present 
some obvious difference such as the sparing of lower motor neurons, the slow rate of disease 
progression, and normal lifespan.  PLS may be mistaken for spastic paraplegia, a hereditary disorder 
of the upper motor neurons that causes spasticity in the legs and usually starts in adolescence.  Most 
neurologists follow the affected individual's clinical course for at least 3 to 4 years before making a 
diagnosis of PLS.  The disorder is not fatal but may affect quality of life 1.   
 
Spinal muscular atrophy (SMA) is a hereditary disease affecting the lower motor neurons.  It is an 
autosomal recessive disorder caused by a mutation in the gene SMN1, which encode for SMN protein 
which have a key role in survival of motor neuron. Indeed, it is known that low level of SMN protein 
cause degeneration n motor neuron.  In SMA patient’s degeneration of the lower motor neurons, 
producing weakness and wasting of the skeletal muscles.   There are three different classes of  SMA, 
caused by defects in the SMN1 gene4, based on ages of onset, severity, and progression of 
symptoms.  . 
SMA type I, also called Werdnig-Hoffmann disease, involve child within 6 months of age.  Symptoms 
may include hypotonia, diminished limb movements, lack of tendon reflexes, fasciculation, tremors, 
swallowing and feeding difficulties, impaired breathing and often are present some skeletal 
abnormalities.  SMN I children can’t sit or stand and usually die because of respiratory failure before 
the age of 2 years4. 
Type II usually begin between 6 and 18 months of age. Also type two patient present respiratory 
difficulties, less than type one. So, despite the life expectancy is reduced, often patient reach 
adolescence or young adulthood. Children may be able to sit but are unable to stand or walk and may 
have respiratory difficulties.   
Symptoms of SMA type III (Kugelberg-Welander disease) appear between 2 and 17 years of age and 
include abnormal gait, difficulty running, climbing steps, or rising from a chair, but they may have a 
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normal lifespan 4 . In this SMA type the lower extremities are most often affected and patients are 
characterized by some  complications include scoliosis and susceptibility  to respiratory infections 4. 
 
Spinobulbar muscular atrophy (SBMA), also known as Kennedy’s disease, is an X-linked recessive 
disease due to a mutation in the androgen receptor gene.  Female are only a carrier of the disease and 
they have a 50 percent chance of having a son affected by the disease.  The onset of symptoms is 
variable, and the disease may first be recognized between 15 and 60 years of age.  Symptoms include 
weakness and atrophy of the facial and tongue muscles, leading to problems with chewing, 
swallowing, and changes in speech 5.  Early symptoms may include muscle pain and fatigue.  Weakness 
in arm and leg muscles closest to the trunk of the body develops over time, with muscle atrophy and 
fasciculations.  Individuals with Kennedy’s disease also develop sensory loss in the feet and 
hands.  Nerve conduction studies confirm that nearly all individuals have a sensory neuropathy (pain 
from sensory nerve inflammation or degeneration). The course of the disorder varies but it is generally 
slowly progressive.  Individuals tend to remain ambulatory until late in the disease.  The life 
expectancy for individuals with Kennedy disease is usually normal 6. 
 
At the moment, there aren’t specific tests to diagnose and discriminate between MNDs, although 
there are genetic tests for SMA, and SBMA.  Indeed, in the early stages of the disease symptoms are 
variable and may be like those of other diseases, making diagnosis difficult.   An important help could 
be a physical exam usually followed by a neurological exam.  Neurological exam can give information 
about nerve function, sensory skills such as hearing, speech and vision ability, balance, coordination 
and changes in behavior or mood 
Nowadays we don’t have a standard treatment to face MNDs, only symptomatic or support treatment 
to help people be comfortable are available. Multidisciplinary clinics, with specialists from neurology, 
physical therapy, respiratory therapy, and social work are particularly important in the care of 
individuals with MNDs.  
FDA approved specific treatment and drug for a few MNDs. Nusinersen (Spinraza) is the first drug 
approved to counteract spinal muscular atrophy in children and adults. The drug is administered by 
intrathecal injection into the fluid surrounding the spinal cord and can induce the expression of SMN 
protein, a key factor for motor neurons survival4.  
For ALS the FDA approved riluzole (Rilutek) that prolongs life by 2-3 months but don’t show any effect 
on symptoms progression.  The drug reduces the body's natural production of the neurotransmitter 
glutamate, which seems to be one of the cause of the disease leading to excitotoxicity.2 
Muscle relaxants such as baclofen, tizanidine, and the benzodiazepines may help reducing spasticity. 
Botulinum toxin may be used to treat jaw spasms or drooling.  Combinations of dextromethorphan 
and quinidine have been shown to reduce pseudobulbar affect.  Anticonvulsants and nonsteroidal 
anti-inflammatory drugs may help relieve pain, and antidepressants may be helpful in treating 
depression. Some individuals may eventually require stronger medicines such as morphine to cope 
with musculoskeletal abnormalities or pain, and opiates are used to provide comfort care in terminal 
stages of the disease 1. 
Usually pharmacological treatment is accompanied by rehabilitation exercise and physical therapy, to 
improve posture, prevent immobility, and reduce muscle weakness and atrophy. Also, simple 
stretching and strengthening exercises may help to reduce spasticity.  
Now many researchers work to find specific treatment or therapy for MNDs taking advantage of all 
possible models and technique with the aim to prevent and repair the damage on the motor neuron.
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Introduction 
Kennedy’s disease  
Kennedy’s disease, from the eponymous neurologist William R. Kennedy who first described the 
principal features in 1968, or spinal and bulbar muscular atrophy (SBMA) is a rare and fatal, 
progressive motor neuron disease (MND) involving different systems and manifesting as androgen 
insensitivity, diabetes, sensory neuropathy and automatic nervous system dysfunction 7. 
SBMA has an estimated incidence of 1/400.000 inhabitants/year, anyway the prevalence of the 
disease can be vastly different from one area to another 8, for example Finland, present a particularly 
large number of affected patients 9. Moreover, SBMA is often not properly diagnosed and frequently 
confused with other neuromuscular diseases, leading to underestimation of its true prevalence. The 
age at onset is between 30 and 50 years 10, and progression of the disease is very slow. The estimated 
disease duration is 27.3 years 11. 
Pathogenesis 
SBMA is an X-linked genetic disorder characterized by an abnormal CAG repetitions expansion. PolyQ 
expanded AR lead to motor neurons in the spinal cord and brain stem. However, we don’t know which 
is the precise mechanisms, that probably involve many different pathway, behind the motor neuron 
degeneration and muscle atrophy 12.  
In healthy conditions, after the interaction between  its ligands testosterone and the more powerful 
dihydrotestosterone, the androgen receptor translocate in to the nucleus where interact with many 
target gene13. In SBMA the main cause of the disease depend on an alteration of the physiological 
function of AR, in addiction the pathological AR tend accumulate and form aggregate interfering with 
normal function of the cells14.  
This characteristic inclusions of polyQ expanded AR can be found in many tissue of SBMA patients  not 
only in motor neurons, such as different parts of the nervous system  but also in liver, skin, kidney 
proximal tubules, testis, prostate and scrotal skin, tissue where androgen receptor result more active 
and exert import function 14. 
Cytoplasmic diffuse accumulations of mutated protein are also being found, but their role in the 
disease pathogenesis in not clear 15. 
The inclusions have a granular aspect with a fibrillary pattern. Those containing mutant AR are usually 
positive for ubiquitin, suggesting that toxicity could be due to an abnormal response to the polyQ tract 
that avoid proteasomes degradation activity Androgen receptors inclusion are granular with fibrillar 
pattern, characterized by ubiquitination, suggesting a failing attempt of proteasome to degrade 
aggregates. 16.  
It is known that not only AR is present in the inclusions, but also other protein such as the chaperones 
Hsp70 and Hsp90, CREB-binding protein (CBP) and other transcription factors are sequestered by 
aggregates. Loss of function of these proteins when sequestered in inclusions could be contributing 
to the disease pathogenesis interfering with physiological cellular function  17.  
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Androgen receptor 
SBMA is due by a mutation on the androgen receptor (AR) gene, which code for the protein of 110-
kDa, a steroid/thyroid hormone receptor family. This receptor mediates the effect of testosterone and 
dihydrotestosterone. Indeed, after the interaction between its ligand, androgen receptor interacts the 
androgen response element in the target genes ad regulate their expression. AR is essential for major 
androgen effects including normal male sexual d and pubertal sexual development 18. The effects of 
AR include sex organs maturation, the growth of pubic hair, the enlargement of vocal cords, the 
production of sperms, the growth of muscle, and the development of masculine behavior. The 
expression of AR is not characteristic only of sexual organ but is widely expressed also in other tissue 
such as kidney, skeletal muscle, adrenal gland, skin, and central nervous system, suggesting it 
influences the majority of the tissues19. Androgen receptor is code by a 90kb DNA sequence that 
contains eight exons coding for specific function domains, located on the chromosome Xq11-12. The 
DNA binding domain is code by the exons 2 and 3 while the exons from 4 to 8 codes for the androgen 
binding domain. The N-terminal, transactivation domain, is characterized by the presence of a CAG 
trinucleotide repeat sequence 20.   
Because of the presence of poly-glutamine repeats, N-terminal domain is a target of structural 
polymorphism. Indeed, the number of CAG repeat is highly variable cause of slippage of DNA 
polymerase during the DNA replication 21. DNA polymerase process could lead to an increase of CAG 
repeat, causes of SBMA, or to a lower number of repetition associated with the increase of the risk of 
prostate cancer, hirsutism, male infertility, and cryptorchidism 22. Therefore  cause of SBMA is the 
expansion of the trinucleotide CAG repeat, which encodes the poly-glutamine tract, in the first exon 
of the AR gene 7. The CAG repeats range size is usually from 9 to 34 in normal subjects, and from 38 
to 62 in SBMA patients 23. As documented in other poly-glutamine diseases, the CAG repeat size 
correlates with the age of onset in SBMA but does not appear to dictate the rate of disease progression 
24.  
 
The presence of polyQ tract on the androgen receptor leads to two mainly consequence, a loss of AR 
physiological function and a gain of toxic function, more evident in motor neurons cells. Moreover, it 
is known that androgens, through androgen receptor, exerts a trophic effect on neuronal cells. So, the 
loss of AR function  may play a role in the pathogenesis of SBMA 25. Expansion of the poly-glutamine 
tract slightly suppresses the transcriptional activities of AR, probably because it disrupts interaction 
between the N-terminal trans-activating domain of the receptor and transcriptional co-activators 15. 
Although this loss of function of AR may contribute to the androgen insensitivity in SBMA.  
It is known that the primary cause of neurodegeneration in SBMA is a gain of toxic function of the 
poly-glutamine expanded AR. Indeed, there are evidence of motor impairment in AR knockout mice  
and also in patient characterized by severe testicular feminization syndrome, lacking of AR function 26. 
One of the main hallmark of SBMA are nuclear inclusions of poly-glutamine expanded AR that are 
found in the residual motor neurons and many other neuronal and non-neuronal tissue27. The 
consequence of this inclusions is not clear. Indeed there are evidence that indicate  inclusions as a 
defense mechanisms against the pathogenic poly-glutamine protein, since sequestering mutant 
protein may lead to a reduction of its toxic activity 17. On the other hand, diffuse accumulation of 
misfolded proteins appear to play an important role in the initiation of neurodegeneration in poly-
glutamine disease 28. The frequency of diffuse nuclear accumulation of the poly-glutamine expanded 
AR in spinal motor neurons strongly correlates with the length of the CAG repeat in the AR gene 13. It 
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seems that polyQ androgen receptor principally accumulate in to the nucleus of motor neurons 
leading to functionality alteration and at the end cell death. But AR is widely expressed, so inclusions 
are detectable not only in central nervous system but also in pancreas and scrotal skin 29. For instance, 
sensory neurons within the dorsal root ganglia often show AR aggregates in the cytoplasm, that appear 
to be associated with axonal degeneration of sensory nerves in SBMA 30, while the cytoplasmic 
deposits of AR in the pancreas likely correspond to diabetes. The presence of an abnormal number of 
CAG repetition interfere with the normal conformation of the protein and altered structure lead to 
aggregation. It is now widely accepted that accumulation of these abnormal proteins in neurons is the 
primary event in the pathogenesis of poly-glutamine diseases31. The oligomeric fibrils formed by the 
poly-glutamine-expanded AR are morphologically and functionally distinct from the annular oligomers 
formed by normal AR proteins 23. Several experimental observations indicate that the formation of 
toxic oligomers or intermediates of abnormal poly-glutamine-containing protein initiates a series of 
cellular events which lead to neurodegeneration32. This hypothesis is also applicable in a mouse model 
of SBMA, in which soluble oligomers are detectable prior to the onset of neuromuscular symptoms33. 
Localization of misfolded proteins in to the nucleus is a key event for cells dysfunction and the 
consequence degeneration, in a poly-glutamine disease.  Interestingly, in cell model of Huntington 
disease, has been proved that insertion of nuclear export signal to sequence of the mutant eliminates 
aggregate formation and cell 34, while a nuclear localization signal has the opposite effect 34. 
Comparable result was obtained for poly-glutamine-expanded AR. Indeed,  a mutation in the 
receptor’s nuclear localization signal or the addition of a nuclear export signal to the protein, results 
in a lower toxicity  suggesting that nuclear localization is essential for toxicity12. Nuclear accumulation 
of the poly-glutamine-expanded AR is followed by several downstream molecular events, that are 
thought to result in neuronal dysfunction and cell death (Figure 1). Ligand-dependent toxicity of poly-
glutamine-expanded AR in SBMA is unique among poly-glutamine diseases in that the pathogenic 
Figure 1 -Under normal conditions AR first interacts with dihydrotestosterone (DHT) or testosterone, then migrates to 
the cell nucleus, where it interacts with specific DNA sequences inducing transcription of androgen target genes. 
Polyglutamine AR also migrates to the nucleus after binding with its ligand and, once in the nucleus, it can no longer 
interact properly with AR target genes. Alteration of this pathway results in abnormal transcription and protein production 
by several genes, which may therefore lose their physiological function (Querin 2016). 
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protein, AR, has a specific ligand, testosterone, which alters the subcellular localization of the protein 
by favoring its nuclear uptake. Unbound androgen receptor is usually in a multi-heteromeric complex 
in the cytoplasm that inactive it functions. AR can translocate in to the nucleus only in ligand-
dependent manner 35. This ligand dependent mechanism play a key role in the pathogenesis of the 
disease and give an explanation for the gender difference which is a specific feature of SBMA 36. The 
gender differences are also observable in animal model of Kennedy’s disease. Indeed, in a  mouse 
expressing the full-length human AR containing 97 CAGs (AR-97Q), neuromuscular symptoms are 
evident only in male mice,  while not  symptoms are detectable in female littermate 36. Male AR-97Q 
mice show more abundant diffuse nuclear inclusion than females, in accordance with the symptomatic 
difference according to gender. Interestingly, because of surgical castration and androgen deprivation 
reduce the symptoms severity and the histopathological evidence. On the other hand, injection of 
testosterone also leads the females to develop the pathology. Since the nuclear translocation of AR is 
ligand-dependent, testosterone represent the trigger event to induce toxicity accelerating nuclear 
translocation of the poly-glutamine-expanded AR. This theory it has also been reported in animal 
model of the disease in which testosterone deprivation by castration reverses motor dysfunction in 
transgenic mice of SBMA 37. Symptoms are minimal in homozygous females for expanded CAG repeat 
in the AR gene, while testosterone administration induced neuromuscular signs of SBMA patient. 
These observations support the ligand-dependent hypothesis38. Recent studies demonstrate that 
while nuclear localization induced by testosterone in necessary for the neurotoxicity, is not sufficient. 
For example, a mutation that inhibits the binding of mutated androgen receptor to DNA but not affect 
ligand binding, don’t lead to neurodegeneration. This evidence suggest a role of DNA binding in the  
AR-mediated neurodegeneration39.. In addition to nuclear translocation and DNA binding, 
testosterone mediates the interaction of the amino- and carboxyl-terminal domains (N/C interaction) 
of AR, which is also required for the toxicity of the poly-glutamine-expanded AR. The ligand-dependent 
interaction between the carboxyl-terminal AF-2 domain of AR and co-regulators is another requisite 
for the toxicity 39. Post-translational modifications have been implicated in the neurotoxicity of the 
poly-glutamine-expanded AR. For instance, in cells the toxicity is decreased by  phosphorylation of 
serine 215 and 792, by reduce affinity between AR and ligand40. It is also known that toxicity is further 
diminished in presence of insulin-like growth factor-1 (IGF-1), able to activate many cell survival 
pathways 41. Moreover, the specific expression in muscle of IGF-1 is able to mitigates neuromuscular 
symptoms and ameliorates both muscle and spinal cord pathology, suggesting that studies on AR 
phosphorylation or androgen receptor manipulation may be a right way to find a therapy. In contrast, 
not all modifications lead to an amelioration. Indeed, the phosphorylation of AR at 514 induce activity 
of caspase-3 increasing AR N-terminal fragment via protein cleavage. Increase of N-terminal fragment 
amount enhancement of the pathogenic AR toxicity in a cellular model. Also other modification such 
as phosphorylation, acetylation and sumoylation seem to modify the toxicity of the poly-glutamine-
expanded AR. Acetylation at lysin 630/632/633 stabilizes the poly-glutamine-expanded AR and 
enhances its cytotoxicity 42. Sirtuin1 (SIRT1), a nicotinamide adenine dinucleotide dependent histone 
deacetylase, suppresses the nuclear accumulation and also toxicity of the pathogenic AR in primary 
motor neurons by de-acetylating the receptor 42, while mutation of lysine 630 or 632 and 633 delays 
the nuclear translocation and induces the formation of cytoplasmic aggregation of AR in a non-
neuronal cell line 43. Sumoylation seems also to increase polyQ AR solubility inhibiting formation of 
inclusion facilitating the clearance44. These observations suggest that acetylation and sumoylation are 
potential targets of therapy development, although their implication in animal models has yet to be 
clarified. Recent studies suggest that also transcriptional alteration could be involved in the 
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pathogenesis of SBMA and other poly-glutamine disease. For instance low levels of heat shock 
proteins (Hsps) were found in SBMA and HD animal models45. Other important factor such as the 
transcriptional co-activators CBP result sequestered in the protein inclusion in both mouse model and 
patient with poly-glutamine diseases46. CBP is an HAT, histone acetyltransferase, able to regulate gene 
transcription by altering the structure of the chromatin. It has already been showed that the activity 
of CBP as HAT is reduce in cells models of poly-glutamine disease, and this transcriptional 
dysregulation may due to a low histone acetylation and cause the pathogenesis of neurodegeneration. 
This hypothesis is confirmed observing that in the spinal cord of SBMA mice the histone H3 acetylation 
is drastically reduced 47. Moreover, the presence of polyQ AR lead to dysregulation in expression of 
several growth factor genes, required for the neuronal survival 41. Testosterone-dependent 
transcriptional dysregulation has also been studied using a Drosophila model of SBMA, in which the 
poly-glutamine-expanded AR enhances an androgen-dependent association of AR with 
Retinoblastoma protein 48. This interaction appears to result in an aberrant E2F transactivation 
through the suppression of histone de-acetylation.  
Another important factor in the neurodegeneration is represent by the obstruction of axonal 
transport, complication that often occurs in MNDs. For example, mutation in the gene coding for 
dynein and dynactin 1, protein that regulate axonal trafficking, are already known. In humans SMBA 
patient and also in rodents models, the mRNA expression of dynactin 1 is reduced, leading to the 
disruption of retrograde axonal transport49.Alteration in axonal trafficking  of motor neurons and the 
blockade of endosomal trafficking are also documented in a knock-in mouse model of SBMA carrying 
AR113Q 28. These deficits are partially rescued by the local administration of VEGF PolyQ androgen 
receptor cytoplasmic inclusion were found also in the axons, where can alter the kinesin localization, 
one of the most important motor for anterograde transport, and so alter also organelles transport35. 
Also fast axonal transport could be affected by the presence of aggregate and inclusion, in both 
anterograde and/or retrograde direction50.   Furthermore, the poly-glutamine-expanded AR activates 
c-Jun N-terminal kinase (JNK), leading to the inhibition of kinesin-1 microtubule-binding activity and 
eventual disruption of anterograde axonal transport 51. It is noteworthy that JNK inhibitors reverse the 
suppression of neurite outgrowth by pathogenic AR in cultured cells 51.  
Mitochondrial impairment is also observed, and it also involves activation of caspase in 
neurodegenerative polyQ disease. Indeed, N-terminal fragments of the poly-glutamine-expanded AR 
may activate an apoptotic pathway via activation of JNK in primary cortical neurons 7. This system 
depends on Bax, a key apoptosis factor able to induce the release of cytochrome C from the 
mitochondria. Furthermore, polyQ AR bind to testosterone seems to altered the membrane 
depolarization ability of mitochondria leading to an increase of reactive oxygen species, which is 
treated with the antioxidants co-enzyme Q10 and idebenone 52. It is also demonstrated that the poly-
glutamine-expanded AR represses the transcription of subunits of peroxisome proliferator-activated 
receptor gamma coactivator-1, a transcriptional co-activator that regulates the expression of various 
nuclear-encoded mitochondrial proteins, suggesting a link between poly-glutamine-mediated 
transcriptional dysregulation and mitochondrial dysfunction 52. 
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Phenotype and symptoms  
The main clinical feature of SBMA is a muscular weakness reported in the 97% of the cases. Symptoms 
usually appears at the age of 35-40 years24. The age of onset could correlate between the number of 
CAG, while seems not affect the disease progression53. Lower limb weakness is the most common 
symptom, followed by upper limb weakness. However, recently many other symptoms have been 
observed, also before the onset of muscle weakness, classically considered the primary sign on the 
disease. For instance, many patient present hand tremor, usually is first manifestation noted by 
patients and appears at a median age of 35 years. Since is a postural high-frequency tremor that may 
result in impairment of daily activities as writing and eating 5.  Other early symptoms could be muscle 
cramps, myalgia, breast enlargement, premature exhaustion during physical exercise and foot 
numbness. Also leg tremor has been observed in a small court of patient, characterized by a high 
number of CAG repetition in the androgen receptor gene. Kennedy disease affect mainly proximal 
lower-limb muscles, so the characteristic manifestation of the disease are represent by difficulty in 
climbing stairs and getting up from a chair5. 
The progression of pathology forces the use of walking aids (handrails, canes, frames and wheelchairs) 
and bulbar-related symptoms (dysarthria and dysphagia) and erectile dysfunction are reported 
between the ages of 50 and 60 years. 
In every stage of the disease are reported fatigue and a reduced tolerance of effort that can limit 
activities of daily living 54. 
A peculiar feature of SBMA is an involvement of brain-stem motor nuclei. This implication result in 
symptoms such as weakness of the masseter muscles leading to tremors of the mouth when is hang 
open. Also tongue is affected characterized by fasciculations with irregularities at the edges or deep 
furrowing in the midline due to wasting 55. Weakness and atrophy in mouth muscle are usually 
associated with vocal-cord paresis, leading to dysarthria and dysphonia, chewing difficulties and 
pharyngeal paresis56. Swallowing dysfunction is found in 80% of cases and is characterized by 
incomplete food bolus clearance through the pharynx 57. Patient are also characterized by nasal voice 
cause of palatal atrophy and also laryngospasm which pathogenesis still is unknown58,59. 
Like other NMD  also in SBMA  respiratory muscles may be progressively involved, while complete 
respiratory failure is uncommon 60.  
Androgen receptor inclusion were find not only in the spinal cord and brain stem, but are present also 
in the cells of dorsal root ganglia, affecting sensory system, vibratory sensation and reduction of 
sensory function in the extremities and several patient present symptoms of weak or absent deep 
tendon reflexes 61.   
The presence of sensory neuropathy may also be associated with neuropathic pain that is mainly 
localized distally in the lower limbs, associated with frequent foot numbness and tingling, as reported 
in up to 58% of patients 62. 
Because of wide androgen receptor expression in many parts of nervous and non-neuronal tissue, 
SBMA is not just a classical neuromuscular disease, indeed patient are also characterized by the 
presence of non-neurologic symptoms  45.  
Endocrine symptoms, depending on AR loss of function, are usually present like as gynecomastia, 
reduced fertility due to testicular atrophy, azoospermia, oligospermia, erectile dysfunction and 
reduced libido 63.  
Abdominal obesity, dyslipidemia, liver dysfunction and glucose intolerance can be also detected in 
some patients, and frequently patients show metabolic syndrome 64. While gynecomastia and other 
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symptoms of androgens insensitivity are due to the loss of AR function, the remaining non-neuronal 
symptoms depend to toxicity of mutant ARs in those tissues 65. Several patients show also signs of 
primary cardiomyopathy and 40% present urological involvement, such as lower urinary tract 
obstruction in the absence of prostatic hypertrophy. These complication lead to patient 
catheterization 66. At the moment the mechanism that cause al this non-neuronal and non-endocrine  
is still not clear 67.  
Extensive accumulation of mutant ARs in the brain of SBMA patients have been demonstrated, and 
recent studies have focused on the consequences of SBMA on the central nervous system 13.  
Indeed, is common for patients with SBMA to have some specific psychological characteristics, such 
as diffidence, marked emotional sensitivity and concentration problems 68. Such observations are 
supported by evidence of altered theory of mind functions related to empathy, which is linked to 
complex frontal lobe functioning 69. Magnetic resonance and electrophysiological studies have 
revealed subclinical abnormalities in the primary motor cortex and other frontal areas of the brain in 
SBMA patients 70,71. A recent study using positron emission tomography (PET) also identified 
hypometabolism in the frontal regions in 10 patients with SBMA 72. 
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Muscle and non-cell autonomous disease 
Traditionally, SBMA has been reported as a cell autonomous primary MND, neuronal death is due to 
a toxic gain of function by PolyQ expanded AR.  
More recently, it has been proposed the hypothesis of a primary myopathy component trigger to the 
pathology development 73. Indeed, there are evidence of muscle involvement such as high creatine 
phosphokinase serum levels and the presence of myogenic changes in muscle biopsies from patients 
74.  
Clues of mixed neurogenic and myopathic processes have also been reported in mouse models of 
SBMA 75. Histopathological analyses of muscle tissues from transgenic and knock-in mice expressing 
polyQ-expanded AR have revealed both neurogenic and myopathic involvement 14,41,76. 
Moreover in knock-in mouse mode of Kennedy’s disease muscle features are evident earlier then 
motoneurons alteration, suggesting a primary role of muscle in SBMA pathogenesis 77.  
It is also known that androgens have an important role in skeletal muscle, for example in their 
development and anabolic action. Androgens in healthy man induce muscle strength, endurance and 
size improving muscle performance. Low level of AR activity in SBMA patient have as a consequence 
a reduction of muscle tissue and an increase of adipose tissue 78.  
It is also possible that polyQ AR induce a toxic response in the satellite cells, responsible for the 
regeneration and development of muscle, leading to deterioration of SBMA muscle. Indeed, while 
androgens and AR result in hypertrophic effects on muscle, in SBMA patient have a detrimental role 
79.  
PolyQ expansion in AR has been proposed to cause toxicity in muscle due to an alteration of gene 
expression. Another important pathway of toxicity in SBMA muscle could be the alteration of RNA 
splicing. However, it remains to be established how these toxic pathways contribute to the 
pathogenesis. 
Damage to motor neurons can also be a consequence of damage in other cell types, such as muscle 
and glial cells, following a non-cell-autonomous toxic process. 
These cells secrete important factors with trophic support activity, which is essential for motor neuron 
maintenance in adulthood 73.  
Two important classes of molecules, which have trophic support activity and can protect neurons by 
initiation of apoptotic pathways and promoting activation of pro-survival pathways, are that of 
neurotrophin and growth factors. It is known that expression of neurotrophin and growth factors is 
altered in mouse models of SBMA 80. This observation highlights the idea that altered trophic support 
to motor neurons from neighboring tissues may be responsible for non-cell autonomous damage in 
SBMA. 
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Diagnosis 
The main way for SBMA diagnosis is a genetic test that can estimates the number of CAG repetition in 
the androgen receptor gene. If the sequence results longer than 38 repetition the subject is 
considerate an SBMA patient81. A second strong approach is the familial history of the patient, could 
be very useful for e first selection and then deepen the analysis by genetic test. Unfortunately 
neurological symptoms are not specific only for SBMA, but endocrine features can be really helpful 
for the diagnosis 1024. An increase of creatine phosphokinase levels may also be an important clue, 
since all patients show very high levels, up to 38 times the normal value, which decrease with 
progression of the disease 82. 
Also, endocrine-related symptoms, like as glucose intolerance or dyslipidemia in association with 
lower motor neuron abnormalities, can suggest a diagnosis of SBMA.  
The diagnosis is often confirmed on electromyography usually performed during the routine analysis 
of motor neuron disease, showing a chronic neurogenic pattern with fasciculations that extend 
beyond the regions affected by weakness 73.   
Also, involvement of sensory system is a clue of SBMA, reduction of sensory sensitivity, in addition, 
muscle biopsy can also be performed, particularly when myopathy is initially suspected. Signs of 
neurogenic atrophy have been described in all patients, including aggregation of type I and II fibers, 
target fibers, atrophied fibers and sub-sarcolemma nuclei clumping. Myopathic alterations are more 
often found in patients with a higher grade of disability 81. 
  
Figure 2 -In the pathogenesis of SBMA, damage to motor neurons can result both from cell-autonomous and non-cell-
autonomous toxic processes, the latter arising in other cell types such as skeletal-muscle cells. These cells are highly 
androgen-sensitive and may alter several physiological pathways after interactions with mutated polyQ-AR (Querin 
2016).  
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Therapy and symptomatic treatment 
Now are available only palliative or symptomatic approach usually focused on rehabilitation and 
exercise to treat SBMA, no specific treatment has yet been found.  One of the main goal to face SBMA  
is preserve muscle and strength as long as possible taking advantage of physical activity or 
physiotherapy exercises81. 
Assist devices for walking are usually necessary, in the most serious cases also a wheelchair could be 
necessary. Muscle cramps are frequent and may be persistent and affecting SBMA patient quality of 
life 24.  
The most part of the symptomatic approaches is necessary to treat neuropathic pain, using classical 
painkillers drugs such as antiepileptics and amitriptyline. 
Treatment of neuropathic pain is based on the classic drugs used for this indication, such as 
antiepileptics and amitriptyline. Speech therapy aims to improve voice modifications and dysarthria. 
Behavioral measures can be established to reduce the risk of aspiration in patients presenting 
significant dysphagia. Nutritional control is useful for weight control 24. 
Aspiration pneumonia is the predominant cause of death and hospitalization in SBMA 83. However, 
patient usually don’t present diaphragm weakness, and only in a few patients are detectable 
ventilation alteration. Expert suggest also regular cardiological monitoring because of increased 
cardiovascular risk that correlate also with diabetes ad metabolic alteration81. 
Young patient can also present reduced fertility, so assisted reproductive technology could be used 
along with genetic counseling for couples that are planning pregnancy. 
Experimental treatments 
In the past several experimental treatments seemed to ameliorate the condition of SBMA models in 
preclinical studies, or were able to delay disease progression, unfortunately none of these attempts 
reached the same result in human trials and in patients. Obviously one of the first target for a therapy 
is to restore or at least to preserve muscle functionality. It is known that in animal model β-agonist 
drugs may induce muscle development and anabolism. For instance, clenbuterol, a β-agonist, can 
increase muscle strength and resistance, but only for few months. Moreover, in mouse clenbuterol 
treatment shows the ability to induce satellite cells activity, leading to an increase of muscle 
development84.  The real efficiency and the safety of this treatment still are to be confirmed. 
A second possible strategy is representing by androgen reduction therapy since disease phenotype 
depends on androgen. In mouse models the use of leuprorelin 85, a drug widely used  in prostate 
cancer, showed evidence of reducing nuclear inclusions. Another possibility,  is to inhibit the action of 
the enzyme 5-reductase, for example using dutasteride, so limiting the conversion of testosterone 
in the more power dihydrotestosterone Both strategies didn’t show any significant improvement of 
muscle strength in clinical trials 84. 
An additional strategy  promising in mice but not in patients consist in the use of histone deacetylase 
inhibitor or microRNA to reduce androgen receptor mRNA expression or increase mRNA 
degradation86.  
Since polyQ expanded AR toxicity is possible only after the interaction between AR and ligand, its 
inhibition, using, for example, the non-steroidal antiandrogen flutamide, may be an ideal target for 
therapy in SBMA. However, no benefits were detectable in transgenic mice. 
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Since the main toxicity of PolyQ AR is due to aggregate formation, also protein degradation system 
could be a possible approach to counteract the pathology, for example through the enhancement of 
autophagy pathway 87. Nevertheless, at the moment this may be unsuccessful in SBMA, as toxic 
mutant protein is localized into the nucleus 88.  
Therapeutic potential of autophagy 
Autophagy plays a critical role in maintaining homeostasis, adapting to stress in both normal and 
pathogenic cells 89.  
In prevention of neurodegenerative diseases 90,91, the role of autophagy is highlighted by removing 
protein aggregates which is not possible via proteasomal degradation. Many studies demonstrate the 
presence of ubiquitin‐containing inclusions occurred via elimination of Atg5 or Atg7 in murine central 
nervous system during embryonic development. These symptoms are also found in many 
neurodegenerative diseases like Alzheimer disease 92. 
For the physiological function of the cells a key mechanism Is the balance between synthesis and 
degradation, possible through two major pathways such as autophagy and proteasome. The primary 
aim of proteasome is to degrade single proteins, while autophagy can sequester big aggregate of 
protein and organelles 
93. 
There are three primary types of autophagy: microautophagy, macroautophagy and a mechanistically 
unrelated process, chaperone-mediated autophagy that only occurs in mammalian cells 94. Both micro 
and macroautophagy can be selective or nonselective and these processes have been best 
characterized in yeast 95. As noted above, the most distinctive feature of macroautophagy is the 
formation of the double-membrane bound phagophore and autophagosome. In contrast, during 
microautophagy the cargos are sequestered by direct invagination or protrusion of the yeast vacuole 
membrane 96. Nonselective autophagy is used for the turnover of bulk cytoplasm under starvation 
conditions, whereas selective autophagy specifically targets damaged or superfluous organelles, 
including mitochondria and peroxisomes, as well as invasive microbes. 
 
Microautophagy is characterized by the sequestration of the materials to degrade  by the vacuole 
through membrane invagination97. Microautophagy is widely study in yeast were is involved in the 
homeostasis of several substrate, including peroxisomes (macropexophagy) 97, damage organelles, 
lipid droplets and also big portion of nucleus98.   
The substrate of microautophagy are characterized by the presence of a KFERQ-like motif recognized 
by HSPA8 99. Microautophagy activity requires some components of the macroautophagy machinery 
for cargo targeting and internalization, including Atg7, Atg8, and Atg9 97. Microautophagy depends 
also on multiple endosomal sorting complexes required for transport (ESCRT) systems 100. In addition, 
the selective uptake of KFERQ-containing proteins by late endosomes during endosomal 
microautophagy depends on HSPA8, reflecting its ability to directly interact with phosphatidylserine 
on the outside endosomal membrane 101. In a similar way, is known that in Saccharomyces cerevisiae 
the chaperone ATPase Hsp104 is necessary to interact with lipid droplets102. Another main character 
of the microautophagy are the chaperones from the HSP70 protein family, but their role is still not 
clear. Notable, the yeast orthologue of mammalian NBR1, autophagy cargo receptor apparently 
underlies an ESCRT-dependent and ubiquitination-dependent microautophagic pathway 103. So, 
microautophagy could be a type of autophagy in which the cargo is directly internalized in small 
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vesicles that form at the surface of the lysosome/vacuole or late endosomes via ESCRT-dependent 
mechanisms. 
 
Chaperone-mediated autophagy (CMA) is a second type of autophagy characterized by the direct 
delivery of cytosolic proteins targeted for degradation to the lysosome 104. The main difference 
between CMA and macro and microautophagy is that in CMA the substrates reach the lysosomal 
through a protein-translocation complex at the lysosomal membrane without intervention of 
membrane invagination or vesicles. Moreover, CMA is able only to degrade protein taking a KFERQ-
like motif and recognized by HSPA8105. CMA has been shown to operate on many of cytosolic proteins, 
exerting a lot of regulatory function, such as metabolic regulation, genome integrity preservation 106, 
aging, neurodegeneration, and oncogenesis 107. It is known that 30% of cytosolic protein are substrate 
for CMA108. The peculiar mechanism that allowed substrates to translocate across lysosomal 
membrane involve specific isoform of LAMP2, LAMP2A.  Thus, chaperone-bound autophagy 
substrates bind LAMP2A monomers on the cytosolic side of the lysosome, which stimulate the 
formation of an oligomeric LAMP2A translocation complex 104. While unfolding and dissociating from 
chaperones, CMA substrates are translocated into the lysosomal lumen through oligomeric LAMP2A 
complexes that are stabilized by a lysosomal pool of heat shock protein HSP90, and a cytosolic pool of 
glial fibrillary acidic protein (GFAP) 104. It remains to be determined to what level CMA is conserved in 
lower organisms, since the splice variant of LAMP2 that is essential for CMA appeared relatively late 
in evolution 109.  
 
Macroautophagy is the variant of autophagy best characterized indeed molecular machinery that 
executes and regulates macroautophagy in organisms is also present in yeast, nematodes, flies, and 
mammals has been the subject of intense investigation throughout the past two decades 110. 
Macroautophagy present easily distinguishable morphological features. Indeed, whereas 
microautophagy and CMA are not associated with major morphological changes in vesicular 
compartments, macroautophagic responses involve vesicles that can occupy a considerable part of 
the cytoplasm 111. These changes depend on formation of a double-membraned vesicles, known as 
autophagosomes. The potential of macroautophagy depend on the ability to sequester big protein 
aggregate or entire organelles. It is also know that macroautophagy has a fundamental role in the 
regulation of cell death 89, muscular fiber atrophy and neurodegeneration 112  
The macroautophagic responses involving the formation of autophagosomes, their fusion with 
lysosomes, and lysosomal degradation have been associated with the activity of two ubiquitin-like 
conjugation systems 110. First ATG7 and ATG10 are involved in inducing the association of ATG5 with 
ATG12 which leads to a multiprotein complex characterized by the presence of autophagy-related 16-
like 1 (ATG16L1) 93. The next system is promoted by ATG3 and ATG7, which together with the ATG12-
ATG5:ATG16L1 complex conjugates phosphatidylethanolamine to microtubule-associated protein 1 
light chain 3 beta, best known as LC3B 113. LC3-II, the lapidated form of  LC3,  is generated on 
developing autophagosomes and allows binding to several autophagy receptors 114. The assembly and 
activation of a multiprotein complex including ATG13, ATG101, RB1 inducible coiled-coil 1 (RB1CC1 or 
FIP200) and unc-51-like autophagy activating kinase 1 (ULK1) at ATG9-containing membranes 
promotes the autophagosome formation. This mechanism is followed by ULK1-dependent ATG9 
phosphorylation 115leading to the elongation of pre-autophagosomal membranes upon incorporation 
of phospholipids from  other organelles such as mitochondria116. This process  permits  the recruitment 
of a multiprotein complex with Class III phosphatidylinositol 3-kinase (PI3K) activity, which contains 
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BECLIN1 , phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), phosphoinositide-3-kinase 
regulatory subunit 4 (PI3KR4) 117, the sensor of membrane curvature ATG14, and nuclear receptor 
binding factor 2 (NRBF2)118 . On activation, VPS34 produces phosphatidylinositol 3-phosphate (PI3P), 
which is essential for the expansion of autophagosomal membranes until closure by engaging PI3P-
binding ATG proteins and members of the WIPI family 119. 
One of the main characters of the autophagic process is the macroautophagy regulations is MTOR 
complex 1 (mTORC1). mTORC1 is able to regulate autophagy by the inactivation of ATG13 and ULK1 
by phosphorylation120, or also preventing the nuclear translocation of transcription factor EB (TFEB), 
a key transcriptional regulator factor of lysosomal biogenesis and macroautophagy 121. mTORC1 
inactivation act by AMP-activated protein kinase (AMPK), which responds to reduced ATP levels and 
consequent AMP accumulation 122. AMPK also catalyzes activating phosphorylation events on ULK1 
and BECN1 123.  
 
 
In mammalian cells, ULK1 directly phosphorylates BECN1, resembling AMPK in its VPS34-stimulatory 
effects and ATG14 106. The autophagy-specific Class III PI3K complex is regulated by several interactors, 
including the VPS34 activator autophagy and beclin 1 regulator 1 (AMBRA1) as well as the BECN1 
inhibitor BCL2, which also interacts with ATG12 124. Once autophagosomes have enclosed autophagy 
substrates, they can fuse with late endosomes or lysosomes to form amphisomes or autolysosomes. 
The molecular machinery that is responsible for these fusion events involve dozens of proteins, most 
of which are shared with the endocytic pathway 125. In this setting, an important role is the activation 
of the GTPase RAB7A, which is required for autophagosome maturation 126, the PI3P-binding protein 
Figure 3 -Schematic depiction of the two main types of yeast autophagy. In macroautophagy, random cytoplasm and 
dysfunctional organelles are sequestered by the expanding phagophore, leading to the formation of the autophagosome. The 
autophagosome subsequently fuses with the vacuole membrane, releasing the autophagic body into the vacuole lumen. 
Eventually, the sequestered cargos are degraded or processed by vacuolar hydrolases. In microautophagy, cargos are directly 
taken up by the invagination of the vacuole membrane, followed by scission, and subsequent lysis, exposing the cargo to 
vacuolar hydrolases for degradation (Feng 2014). 
 Chapter 1 - Introduction 
23 
 
tectonin beta-propeller repeat containing 1 (TECPR1), ectopic P-granules autophagy protein 5 
homolog (EPG5), inositol polyphosphate-5- phosphatase E (INPP5E) 127, and other soluble N-
ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins, as well as homotypic 
fusion and vacuole protein sorting (HOPS) complexes 128. ATG14, LAMP2B as well as phosphorylated 
and lipidated LC3 are also involved in the formation of autolysosomes 129. On the other hand, RUN and 
cysteine-rich domain containing BECLIN 1 interacting protein (RUBICON) negatively regulates the 
fusion of autophagosomes with lysosomes upon interacting with VPS34 130. Degradation of autophagy 
substrates proceeds through the lysosomal lumen that is acidified, upon disassembly of the inner 
autophagosomal membrane supported by the ATG conjugation systems 131. Lastly, mTORC1 
reactivation inhibits macroautophagy as it promotes leading to autophagic lysosome reformation 
(ALR), a process essential to regenerate the lysosomal compartment 132. 
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Trehalose 
Trehalose is a natural disaccharide sugar found broadly but not abundantly among miscellaneous 
organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein 
denaturation, it plays various protective roles against stress conditions such as heat, low temperature, 
oxidation, desiccation and dehydration 133. 
In preliminary research the protective role of trehalose was attributed to its nature of chemical 
chaperone, able to directly interact with proteins, inducing the correct folding. This protective activity 
of trehalose was observed not only in yeast, where trehalose is easily find, but also in mammals, where 
it is not endogenously synthesized. For instance, trehalose now is use to prevent crystallization of 
hydrated protein in cryopreservation of cells134. 
 A second important role of trehalose is the ability to induce the autophagy pathway in an mTOR‐ 
independent manner, observable analyzing others important autophagy factors such as  LC3‐II and 
Atg5, which are associated to autophagosome structure135. 
Additionally, it was demonstrated that trehalose decreases the damage of the blood brain barrier 
caused by MPTP, a neurotoxin which causes permanent symptoms of Parkinson's disease, through the 
recovery of the levels of tight junctional proteins 136. The protective role of trehalose was observed in 
the treatment of many neurodegenerative disorders, usually characterized by inclusion formation or 
anomalous proteins folding, leading to neuronal dysfunction 137. Aggregation of proteins in neurons 
and glia takes place through several mechanisms including mutation, overproduction or impairment 
of its degradation; however, these mechanisms are not fully understood 138. Recently DeBosch and 
coworkers 139 studied the effects of trehalose on hepatic lipid accumulation and discovered that 
trehalose increases autophagic flux by inducing a starvation-like state, decoupled from food intake.  
Indeed, they observed that trehalose can inhibit the activity of glucose transporters at the plasma 
membrane. The receptors manly affected by trehalose inhibition are GLUT1, GLUT2, GLUT3, GLUT4, 
andGLUT8, and their inhibition result in the  activation of adenosine monophosphate kinase (AMPK) 
and the phosphorylation of ULK1 (the autophagy inducer kinase) 140. The first treatment with trehalose 
in neurodegenerative disease was conducted in a mouse model of Huntington’s disease, characterized 
by aggregates of the mutant huntingtin protein. Trehalose treatment was able to reduce the 
symptoms and reduce inclusion formation. As a consequence there was also an increase of mouse 
motor coordination and survival 141. A similar therapeutic outcome was observed in a mouse model of 
amyotrophic lateral sclerosis (ALS), in which trehalose administration enhanced autophagic clearance 
of aggregates of mutant superoxide dismutase 1 (SOD1). Likewise, trehalose induced autophagy and 
had protective effects in a mouse model of tauopathy, one of the hallmarks of Alzheimer’s disease 142. 
Moreover, more detailed in vitro studies suggest that trehalose may induce aggregate degradation 
enhancing autophagy through a mechanism that is independent of the autophagy regulating activity 
of the kinase mammalian target of rapamycin (mTOR) 137. Trehalose mediated increase in autophagy 
was associated with higher expression of key autophagy related genes and activation of the 
transcription factor FoxO1, a regulator of autophagy in neurons 143. These examples illustrate the 
beneficial effects of trehalose in a disease context and point to an alternative route of autophagy 
induction, which could circumvent the side effects of mTOR inhibition 144. 
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In the context of NAFLD (nonalcoholic fatty liver disease), study by DeBosch and coworkers brings new 
insights into the biological activity of trehalose. Primary in the hepatocytes, an also in other cells type, 
trehalose can inhibit the action of SLC2A family transporters, which are necessary for hexose import. 
This inhibition, leads to a reduction in glucose availability and then to a phosphorylation and activation 
of AMPK and a concomitant increase in ULK1 phosphorylation and activation, which induced 
autophagy. Although canonical mTOR targets were not evaluated directly, the dephosphorylation of 
ULK1 in the site regulated by mTOR (Ser757) suggests a potential connection between both autophagy 
regulating pathways. Now there are no information about how and if trehalose compromises glucose 
transport into neurons through GLUT3. If so, this mechanism of enhancing neuronal autophagy 
through the AMPK pathway may explain some of the broad neuroprotective effects of trehalose. A 
general consideration of the study highlights the potential influence of trehalose on global 
carbohydrate and energy metabolism, depending on its administration route. The inhibition of GLUT 
transporters predicts additional metabolic consequences in vivo because GLUT2 is also involved in 
facilitating trans epithelial hexose transport in the gut, whereas GLUT8 facilitates fructose import into 
hepatocytes, and GLUT4 mediates the regulated transport of glucose into adipocytes 140. 
Trehalose has been already tested in many disease models resulting a promising treatment, including 
neuronal and non-neuronal ones, both in-vivo and in-vitro 98. In ALS and FTD autophagy induced by 
trehalose seems to an amelioration of symptoms and to a delay in disease progression in vivo or vitro 
Figure 4 -Trehalose inhibits cellular import of glucose and fructose through SLC2A (GLUT) transporters, generating a 
starvation-like (low adenosine triphosphate) state that stimulates autophagy through AMPK and activation of ULK1. This 
pathway triggers autophagosome biogenesis and autophagic flux, which favors the clearance of pathological protein 
aggregates and lipid stores. Conversely, autophagy is inhibited by mTOR, a sensor of nutrient availability and recipient of 
growth factor signaling. AMPK activation may interfere with mTOR-mediated inactivation of ULK1. Trehalose may induce 
autophagy through additional unidentified mTOR-independent mechanisms (Mardones 2016). 
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test. Unfortunately, now more of this trial are restricted to only in vitro models.  Definitively, clinical 
trials are needed to demonstrate a role of trehalose in controlling the development of 
neurodegenerative diseases and cancer.  
Huntington's disease (HD) is a hereditary disorder cause by a progressive degeneration of nerve cells 
in brain. Neuron degeneration is due by CAG trinucleotide elongation, causing an abnormal long 
polyglutamine (polyQ) tract in the N terminal of the huntingtin protein leading to a misfolded protein. 
This mechanism lead to a formation of amyloid fibrils 145,146. The toxicity is exerted by deficient RNA 
synthesis or ubiquitin proteasome system inefficiency, generating cellular deposits and at the end, cell 
death 147. 
The first protective effect of trehalose is its binding to expanded polyQ and stabilization of the toxic 
mutant protein, and to an enhanced clearance of soluble mutant huntingtin. Another activity of 
trehalose is the triggering of autophagy, through a mTOR‐independent mechanism, protecting cells 
from the subsequent mitochondria‐dependent pro‐apoptotic damage 137. In addition, trehalose‐
induced solubilization of 103Q‐htt protein results in the overexpression of the heat shock protein, 
Hsp104, which, finally, decreases the oxidative stress, the cell death and rescues endocytosis process 
148. In a study to discover the epoxomicin and trehalose co‐treatment effects on skin fibroblasts HD 
patients, it was found that trehalose have some desirable effects including reverting the effects of 
epoxomicin, protecting against huntingtin and polyubiquitinated protein deposits as well as pro‐
apoptotic pathways induced by caspase‐3 in HD human skin fibroblasts, rising the number of skin 
proliferative cells and decreasing reactive oxygen species 149. Additionally, it is reported that co‐
treatment with trehalose and europium hydroxide nanorods enhances autophagy through different 
pathways 149. 
Huntingtin inclusions were also found in non-neuronal cells in brain147. For instance in glial cells which 
are important for their support in neuronal functions and survival150. Inclusions were observed also in 
astrocytes and microglia leading to their function alteration and to a detriment of neurons.  
Therefore, HD glial cultures are more prone to stress oxidative injury, particularly through HDAC6 
activation, to activate protective chaperones as well as formation of aggregations, and are less 
responsive than WT glial cultures to hydrogen‐peroxide‐ induced toxicity 151. Indeed, trehalose 
treatment can reduce microglia activity, the HDAC6 expression an also decrease the inflammatory 
activation usually induced by epoxomicin in both HD and healthy astrocyte. Moreover, it is observed 
an increase of mitochondrial numbers and size and an and enhancement in the number of gliofibrillar 
acidic protein (GFAP+). It is also detected an increase in the synthesis of neurotrophic factor in 
astrocyte, leading to an increase of stimuli for dopaminergic neurons survival. Trehalose, through its 
capacity to induce autophagy, also prevents p62/SQSTM1 aggregation and enhances the degradation 
of cytoplasmic accumulations from mHTT and α‐synuclein proteins 151. 
 
Prion disease are categorized as neurodegenerative disorders resulted from misfolded forms of the 
prion protein, which are proteinaceous infectious particles, and are reported among humans and 
many type of animal species 152. The peculiarities of prion disease are the conversions of the healthy 
prion protein (PrPC) in to an infectious isoform (PrPsc), able to aggregate in the patient brain and, 
finally, lead it to death. Trehalose effect are also tested in this condition, and can induce the autophagy 
flux and reduce the amount of PrPsc in a time and dose dependent manner153. Moreover, the 
treatment can also induce the clearance of PrPsc in infected cells. With the help of some autophagy 
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inducers like trehalose, rapamycin and imatinib, it is suggested that autophagy might have a role in 
physiological breakdown of cellular PrPsc 154 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder which influences motoneurons 
responsible for controlling voluntary muscle movement. Sporadic forms of ALS are 90% of the cases, 
and mutation in TARDBP, FUS, or SOD1 are associated with this disorder 155.  Mutation in the same 
gene are reported for familiar forms of the disease156. Misfolding of SOD1 is the most studied mutation 
, an anomalous [CuZn] superoxide dismutase found in tissues of ALS patients, is toxic for cells as it 
induces many organelles’ dysfunction and accounts for one‐fifth of familial ALS 118. 
It was proved that mutant SOD1 aggregation could be reduced by trehalose treatment in cells. Other 
studies suggest that trehalose are also able to extend longevity and to postpone the progression of 
disease157.  The mechanism is still unknow, but some result suggests an autophagy activation followed 
by FOXO1 induction. This may  prevents the cell‐ nonautonomous effects of glia over primary motor 
neurons, protects mitochondria and ameliorate the transcription of autophagy‐regulatory genes143.   
 
Parkinson's disease (PD) is a common progressive neurological disorder that affects movement and 
is characterized by a massive loss of nigrostriatal dopaminergic neurons. The main cause of the disease 
is the formation of Lewy body, intraneuronal aggregates usually of α‐synuclein (α‐Syn), present in both 
familiar and sporadic PD 158. Therefore, usually PD is characterized by high level expression of 
inflammatory cytokines from glial cells. The disease is due by a mutation in  Park‐2 gene coding for 
parkin, a protein with ubiquitin ligase function159.  In preliminary experiments, autophagy inducers 
such as rapamycin help the elimination of α‐Syn 160, whilst autophagy inhibitors augment its 
accumulation 161. 
Also the effects of trehalose was assessed in vitro model of PD, showing that trehalose treatment is 
able to enhance the clearance of mutant form of α‐Syn158. 
 Moreover, trehalose not only enhance macroautophagy flux, but also increases the autophagosomes 
and decreases cell viability; however, the latter effect is not specifically due to trehalose, but it is 
common among disaccharides, indicating that changes in osmolality might account for reduced cell 
viability. Interestingly, trehalose can also delay aging, a process attributed to PD pathogenesis, and 
extend longevity 162. Trehalose treatment in PD it is also clear in rodent model. Indeed, autophagy 
improve  leading to a reduction of α‐synuclein deposition in substantia nigra, with the subsequent 
effect of enhance dopamine neuronal survival 163. 
 
 
Amyloid pathology (Alzheimer's disease AD) is the most prevalent type of dementia, which induces 
memory loss and leads to problems with thinking and behavior. Small anesthetics, both in vitro and in 
vivo, show pro‐amyloidogenic properties 164, which increase the behavioral anomalies and brain 
lesions in patients with Alzheimer's disease. The sequential proteolytic process of β‐ and ϒ‐secretase 
on amyloid precursor protein lead to Aβ‐amyloid generation. The interaction between the Aβ‐amyloid 
(Aβ) and the lipid bilayer membranes triggers molecular mechanisms crucial for the progress of AD165. 
165. Trehalose treatment seems to reduce Aβ‐amyloid generation and secretion166, reducing also 
amyloidogenesis167  and β‐amyloid accumulation in vitro model168.  
To investigate the role of trehalose in amyloid pathology Induced by isoflurane anesthesia, research 
into APPs mice, which expresses the human mutation of the amyloid precursor protein, treated with 
isoflurane has been carried out. Also, in this case trehalose can help to counteract the effect of 
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isoflurane, such as prevent increase of pro‐apoptotic proteins and apoptosis in the hippocampus. 
Furthermore, isoflurane leads to increased expression of GFAP reducing hippocampal tau expression 
and trehalose again reverts these effects. As a preventive agent, trehalose enhances autophagic 
markers and chaperones, thereby inhibiting accumulation of β‐ amyloid 168. 
Additional research suggests that trehalose damages the metabolism of amyloid precursor protein 
(APP) and vesicular transport but does not prevent ϒ‐secretase activity. This selective inhibition is 
reported to be m‐TOR‐dependent. It also results in high deposition of the autophagic marker proteins 
LC3‐II and p62, and decreased processing of Cat D, an abundant aspartic endopeptidase in lysosomes. 
However, it should be taken into consideration that proteasome pathway, in parallel with autophagy 
is needed to decrease aggregated proteins 129. 
 
Tauopathy are a big family of neurodegenerative disease due by an accumulation of tau protein in 
neurofibrillary or gliofibrillary tangles in human brains 68.  Some of them depend of post‐translational 
changes of tau, usually caused by a different mutations of the Tau gene 169. Tau deposit is a common 
pathologic finding of AD 168 as knockdown of tau expression removes Aβ‐induced neurodegeneration 
in different species 170.  
As result of trehalose treatment in mouse showing parkinsonism symptoms, it is found increase of 
dopamine neurons and the increase of dopamine‐related protein levels in the striatum. Also, an 
increase of aberrant protein clearance is observed through augmentation of autophagy168. 
Furthermore, trehalose enhances motor and cognitive behavior of this species and reduces tau 
abnormalities, astrogliosis and the number of murine β‐amyloid plaques. On the other hand, a long-
term enhancement of autophagy may result in neurodegeneration. An additional role of trehalose is 
to help the degradation of mutant tau through chemical chaperone activity. To compare proteasome 
with autophagy, on the other hand, it is declared that not only proteasome does not have a 
considerable role in tau breakdown in primary neurons 171, but also its inhibition activates some yet 
unknown pathways which decrease the level of endogenous tau; however, this depends on the cell 
type according to some investigations performed on non‐neuronal cell lines 172. Another important 
topic in this regard is to examine the effect of phosphorylation on the autophagic degeneration, which 
results in the minor interaction between them 171. 
 
Hereditary ataxias (HA) is a neurological disorder often characterized by slow progressive 
degeneration of cerebellum. A lot of gene seem to be involved in HA. One of this is CHIP, a ubiquitin 
ligase which act as a bridge between proteasome system and chaperones173. Moreover, it is known 
that CHIP is a key factor for the ubiquitination and degradation of proteins like tau and α‐synuclein 
and therefore, it plays a vital role in other neurological diseases. In several studies was observed that 
mutation in STUB‐1 gene lead to low autophagy activity and variation in CHIP and HSP70 levels 174.. 
Trehalose was tested in vitro, fibroblasts of a patient with ataxia with mutation in CHIP. Cells were 
treated with both epoxomicin and trehalose in vitro. Treatment with epoxomicin induced proteasome 
inhibition, pathophysiological age‐related alteration, protein ubiquitination and reduction in cell 
viability. Treatment with trehalose reduced epoxomicin effect, and an increase of CHIP and HSP70 was 
evident. Moreover, trehalose treatment reduce caspase‐3 and free radical expression and enhancing 
mitochondrial morphology in both untreated and CHIP‐mutant fibroblasts. Moreover, markers of 
autophagy were increased during this process, indicating the activation of autophagy, the most 
beneficial effect of this disorder, in both mentioned groups  
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Frontotemporal degeneration (FTD) and fronto‐temporal lobar degeneration (FTLD), is a disease 
process that results in progressive damage to the temporal and/or frontal lobes of the brain. FTD is 
due by low expression of progranulin, a pleiotropic factor essential for neuron survival175. Low levels 
of progranulin may induce neurodegeneration leading to loss of function by reducing GRN mRNA and 
PGRN protein by at least 50% via haplo‐insufficiency 90. PGRN partially regulates lysosome 
homeostasis, which itself is associated with regulation of GRN expression 176. The main strategy to 
counteract FTD is to increase levels of PGRN, and trehalose and mTOR inhibitors have been found to 
increase PGRN expression and to induce autophagy.  
Although, they all augment both intracellular and secreted PGRN, mTOR inhibitors fail to increase 
PGRN in human and mouse neuroblastoma cell lines, whilst trehalose is shown to have this ability, 
too. Therefore, mTOR‐inhibition and PGRN upregulation are shown to be independent pathways. 
Trehalose mainly acts by enhancing GRN gene transcription, although transcription factor EB (TFEB), 
which is strongly regulated by mTOR phosphorylation, does not affect it 177. 
Spinal and bulbar muscular atrophy and trehalose 
Data obtained in our laboratory and published by Giorgetti 87, examine trehalose effects on SBMA 
suggests that trehalose decreases ARpolyQ insoluble forms in vitro and stimulates HSPB8, which 
enhances solubility and elimination of ARpolyQ via both autophagy and ubiquitin proteasome system. 
Furthermore, cotreatment with anti-androgen Bicalutamide attenuates AR activation and nuclear 
translocation, and increases the efficiency of this treatment, even in the presence of testosterone. 
This combination, also, removes insoluble species of AR with a very long polyQ (Q112) tract. Now for 
this disease in vivo analysis are not available.  
Mouse models of Kennedy disease  
Transgenic mice overexpressing ubiquitously an androgen receptor characterized by 97Q were 
obtained by random insertion of a cassette composed of the cytomegalovirus immediate early 
enhancer, the chicken beta-actin promoter and AR97Q 14.Transgenic mice with ubiquitous 
overexpression of poly-glutamine-expanded AR were generated by random insertion of a cassette 
composed of the cytomegalovirus immediate early enhancer, the chicken beta-actin promoter and 
AR97Q 14. AR97Q-expressing male mice show progressive motor impairment, body weight loss, short 
life span (50 % mortality at 5 months of age), reduced cage activity, and severe muscle atrophy starting 
from 2 months of age in males and 4 months of age in females. Pathological phenotype of AR 97Q 
transgenic mice is androgen dependent, since all symptom can be attenuated by chemical or surgical 
castration14.  This mouse model shows several symptoms also present in human patient. Androgen 
receptor transgene can be detected in the spinal cord, cerebellum, heart, muscle, pancreas, and other 
tissues, and in most of them inclusion formation or nuclear staining for AR can be detected.   Muscle 
pathology is characterized by grouped, small angulated fibers, and reduced fiber size 14, together with 
very large fibers with central nuclei 41. No significant reduction in the number of spinal motor neurons 
has been detected. Interestingly, the diameter of large myelinated fibers is reduced, and no defects 
in the cerebellum, cerebrum, and dorsal root ganglia have been detected.  
A second mouse model of the disease is represented by transgenic SBMA mice with selective 
expression of poly-glutamine expanded AR in neurons, generated by random insertion of a cassette in 
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which the expression of AR112Q transgenes was driven by the prion promoter 74. Male mice of this 
model are not smaller, and they didn’t show lower survival than their wild type littermates. In this 
model only, male show symptoms of slowly progressing motor dysfunction. Indeed, male AR112Q 
present clasping starting to 6 weeks an age, rotarod deficits at 4 months of age, and gait abnormality 
around 7 months of age, open field activity shows reduced vertical and horizontal activity by 7 months 
of age, and grip strength is reduced by 10 months of age. AR112Q transgenic mice show androgen 
receptor inclusions in neuronal tissue. Also, in this case, all symptoms are androgen dependent since 
all symptom can be attenuated by chemical or surgical castration. Because these mice express the 
transgene in the central nervous system but not in skeletal muscle or other peripheral tissues, this 
model allows for investigation of cell-autonomous mechanisms of degeneration in neurons and non-
cell-autonomous degeneration of peripheral organs.  
By homologous recombination, it is possible to generate mice expressing a mutant gene by replacing 
the wild type counterpart, the knock-in technology. This strategy allows to avoid the possible problem 
of overexpressed gene since the mutant gene is finely regulated by the endogenous promoter and 
regulatory sequences, such as enhancers. Knock-in SBMA mice have been generated by replacing the 
mouse exon 1 of AR, located on the X chromosome, with the human exon 1  113 glutamine residues 
178. AR113Q-expressing mice recapitulate several features of human disease. AR113Q-expressing mice 
show a phenotype characterized by premature death at approximately 3–5 months of age 75. 
Premature death is associated with dysfunction of the urinary tract and atrophy of the levator ani/ 
bulbocavernosus muscles. Male AR113Q-expressing mice develop muscle atrophy, body weight loss, 
and motor dysfunction. AR113Q-expressing male mice also show partial androgen insensitivity, 
reduced fertility, and atrophic testes, although serum testosterone levels are like control mice. In 
these mice, muscle pathology is characterized by the presence of both neurogenic and myogenic signs, 
with upregulation of several denervation markers. Because expression of poly-glutamine-expanded 
AR in this model is physiologically regulated, this model allows for in vivo analysis of pathogenic 
mechanisms in a context in which poly-glutamine-expanded AR is not overexpressed. 
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Aim 
In previous in vitro studies conducted in our laboratories it was evaluated whether a combined 
pharmacological treatment, aimed both to reduce the nuclear toxicity exerted by mutant AR and to 
enhance its autophagic clearance, may be a novel therapeutic approach for SBMA.  
These experiments suggest that a co-treatment with bicalutamide, known to lead to a reduction in 
nuclear translocation of androgen receptor, and trehalose can induce an increase in AR nuclear 
inclusions in vitro in presence of testosterone. This study was focused on motoneuronal cells; remain 
to be determined whether the therapeutic approach here postulated may have beneficial effects also 
in muscle, in which the toxicity exerted by ARpolyQ may be due to different causes. 
Interestingly both single treatment and the combined treatment seems to don’t affect the amount of 
soluble ARpolyQ, both in presence or absence of testosterone. Indeed, the degradative induction 
promoted by the two compounds, involves only ARpolyQ misfolded protein, in a synergic manner. 
Therefore, the combined treatment can limit the formation of aggregate and inclusions in 
immortalized motor neurons. These in vitro data suggest that, at least in their earlier formation stages, 
aggregates may protect against ARpolyQ toxicity by confining neurotoxic species into a physically 
defined subcellular compartment.  
However, they become toxic at later stages by altering essential neuronal processes. Moreover, 
aggregate and inclusion may be an important hallmark through observe misfolding protein behavior, 
and its amount reduction usually represent a positive effect of the treatment and in our tests, 
trehalose and bicalutamide combined were more efficiently in aggregate reduction than when the 
same compounds were used separately. 
Therefore, the longer ARpolyQ cytoplasmic retention by bicalutamide facilitates a better cytoplasmic 
autophagic recognition of the misfolded species prior to its migration into the nucleus; at the same 
time, the enhanced autophagy by trehalose improves the capability of this proteolytic system to clear 
the excess of misfolded ARpolyQ released from accessory chaperones after ligand interaction, also 
preventing any possible autophagic flux blockage.  
This goal can be reached by trehalose treatment, able to induce HSPB8, which is a known autophagy 
facilitator. Indeed, many heat shock proteins are involved in the cells response to protein misfolding. 
 For instance, HSPB8 dramatically increases solubility and clearance of ARpolyQ (and other misfolded 
proteins), decreasing their aggregation rate. HSPB8 can induce clearance by both the UPS and 
autophagy; when autophagy is involved, HSPB8 lead to formation of a complex with 
BAG3/HSC70/CHIP, in which CHIP ubiquitinates HSPB8-associated substrates, permit to SQSTM1/p62  
to recognize specific signal in autophagosome.  With this mechanism, HSPB8 facilitates ARpolyQ 
autophagic clearance and relieves the blockage of autophagic flux.  
Several advantages may arise from the use of these two active compounds in SBMA. First, the 
antiandrogen bicalutamide is an FDA-approved and commercially available drug, already widely used 
in prostate cancer therapy. It can be administered for chronic treatment and it is relatively well 
tolerated by patients. Secondly, trehalose is not considered a drug, but a nutrient supplement, with 
no restriction for its oral intake. 
Even if trehalose has been found active in cellular models of SBMA, no studies have been conducted 
in mouse models of SBMA. Similarly, several studies performed in cellular models of SBMA have 
demonstrated that bicalutamide alone counteracts ARpolyQ aggregation possibly facilitating the 
autophagic removal of ARpolyQ misfolded species, thus preventing their neurotoxicity. Even in this 
case, no data are yet available in mouse models of SBMA. We have also tested the combinatory use 
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of bicalutamide and trehalose on cell models of SBMA, demonstrating a synergistic effect of the two 
compounds on ARpolyQ removal. The slowed kinetics of ARpolyQ nuclear translocation induced by 
bicalutamide allows for an increased clearance of misfolded ARpolyQ species via the cytoplasmic 
autophagic machinery, made more efficient and active by trehalose treatment. It is worth noting that 
the autophagic process is induced by trehalose but not influenced by bicalutamide, as shown by the 
two well-known autophagic markers, SQSTM1/p62 and LC3-II. Collectively, the data published by 
Giorgetti et al. in 2015 lay the foundation for preclinical trials in SBMA mouse models to test the 
therapeutic potential of bicalutamide and trehalose in single or combined administration. We choose 
the “Knock-in SBMA mouse” as model. It is characterized by 113 polyQ. The non-transgenic littermates 
were used as control. 
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Results  
Model characterization  
First, to verify the reliability of the animal model selected for this study, we characterized the mouse 
colony with a set of preliminary tests and analyses.  
Mice with a targeted insertion of 113 CAG repeats into exon 1 of the AR gene (see “Materials and 
Methods” section) were examined for evidence of an androgen dependent neuromuscular 
phenotype. 
We found that AR113Q males show a significantly lower body mass than NTg males at all ages 
examined starting from 20 weeks of age (Figure 5A). 
Analysis of survival revealed that AR113Q males die at young age. As shown in Figure 5B, 
approximately 39% of AR113Q males survive at 52 weeks. We observed that the KI AR113Q mice death 
occurs between 16 and 36 weeks, while no NTg mice died in this same period.  
The seminal vesicle weight analysis is a further sign of AR loss of function or alteration, and we found 
that seminal vesicle weight of KI mice at the age of sacrifice, 52 weeks, were smaller than that of NTg 
littermates at the same age (Figure 5C).  
 
 
 
Figure 5 – Preliminary characterization of SBMA mouse model – (A) Body mass (mean ± SEM) reported by age of NTg mice 
(green line, n=14), KI AR113Q (red line, n=17). (B) Kaplan-Mayer survival curve of NTg mice (green line, n=14), and KI 
AR113Q (red line, n=17). (C) seminal vesicle weight of NTg mice (green n=11) and KI AR113Q (red n=9) at 24 weeks of age 
(**p<0.01 by unpaired Student’s t test) normalized to the mouse weight. 
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We performed forelimb grip strength analysis on NTg and AR113Q mice, that is a simple test allowing 
evaluation of the muscular strength of animals. We find that SBMA male mice have a significantly 
decreased forelimb strength compared with wild type mice (Figure 6B). This deficit appeared in adults 
as early as 20 weeks of age, correlating with the decrease in the body mass (Figure 5A).  At the same 
time AR113Q mice show also a worse performance than non-transgenic mice on rotarod, suggesting 
a reduction of motor coordination (Figure 6A). 
 
 
 
Figure 6 - Behavior analysis - (A) Rotarod test (mean ± SEM) of NTg mice (green line, n=14), KI AR113Q (red line, n=17) 
evaluated weekly beginning at 10 weeks age until the age of sacrifice (52 weeks). (B) Forelimb grip strength (mean ± SEM) 
of NTg mice (green line, n=14), KI AR113Q (red line, n=17) evaluated weekly beginning at 10 weeks until the age of sacrifice 
(52 weeks) 
The functional deficit of motor behavior of AR113Q males was accompanied by morphological changes 
in skeletal muscle indicative of both neurogenic and myopathic effects, like the features described in 
muscle biopsies of Kennedy disease patient27.  The skeletal muscle of AR113Q male mice (24 weeks) 
analyzed (gastrocnemius) contained groups of angulated, mild atrophic fibers suggestive of 
neurogenic atrophy (Figure 7D, 7E). Histological analyses revealed also the presence in Tg mouse 
muscle of fibers smaller than that of Ntg (Figure 7A, 7B). On the contrary, we did not find an increase 
of internal nuclei, usually indicative of a myopathic process (Figure 7C). 
To determine whether changes in the gene expression reflect muscle health and denervation, we 
performed real-time RT-PCR to measure the levels of mRNAs coding for myogenin, acetylcholine 
receptor α-subunit and myogenic differentiation antigen also known as MyoD. Usually, the expression 
of these markers is induced following denervation 179. 
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Figure 7- Gastrocnemius morphology - A, B) Analysis of gastrocnemius muscles fiber size (A, maximum Feret diameter; B, 
minimum Feret diameter) from NTg (green) and KI AR113Q (red) mice at 24 weeks of age (symptomatic stage). Neurolucida 
analysis on a section of 40 µm. Each bar represents the mean  sem of four independent replicates (**p<0.01). Statistical 
analysis has been performed through Student’s t test. C) Analysis of gastrocnemius muscles centralized nuclei from NTg 
(green) and KI AR113Q (red) mice. Neurolucida analysis on a section of 40 µm. Each bar represents the mean  sem of four 
independent replicates (**p<0.01). Statistical analysis has been performed through Student’s t test. (D, E) The morphology 
of the muscles (gastrocnemius) is highlighted by hematoxylin/eosin staining. Scale bar = 50 μm 
 
  
AR113Q gastrocnemius muscle expressed 5-fold higher levels of acetylcholine receptor α-subunit at 
symptomatic stage, 24 weeks of age, and 7-fold higher levels at end stage, 52 weeks of age, both 
compared with NTg littermates (Figure 8A). Expression of MyoD and MyoG mRNA did not show 
significant changes (Figure 8B, 8C). We also analyzed the mRNA expression of Pax7, a characteristic 
marker of muscle satellite cells, staminal cells able to differentiate to skeletal muscle cells, and to give 
rise to other satellite cells. Pax7 expression is a clue of regenerative attempt in muscle. In our mice 
gastrocnemius samples, we found 2-fold higher levels of Pax7 at symptomatic (24 weeks), and end 
stage (52 weeks) (Figure 8D).  
 
 
KI AR113Q NTG 50μm 
D E 
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Figure 8 – Expression of muscular markers- RT-qPCR analyses of the mRNA levels of AchR (A), MyoD (B), MyoG (C), Pax7(D) 
performed on total RNA extracted from gastrocnemius of male NTg mice (green) and KI AR113Q (red) at 24 (symptomatic 
stage) or 52 (end stage) weeks of age. Data have been normalized to Rplp0 mRNA, expressed relative to the levels determined 
in NTg mice at 24 weeks of age, which are taken as internal reference, and expressed as fold changes. Each bar represents the 
mean  s.e.m. of five independent replicates (*p<0.05, ***p<0.001). Statistical analysis has been performed through two-way 
ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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Treatment validation  
The dose of trehalose used in this study was selected on the basis of previous reports for other 
neurodegenerative disease, such as Parkinson’s and Huntington’s diseases 163, while the dose of 
bicalutamide  was selected on the basis of that classically adopted in human therapy 180, since this 
drug is widely used in clinics against prostate cancer, and its pharmacokinetics is very well known. 
Preliminary studies were performed to validate both the doses and the route of administration. These 
studies were done by treating 5 NTg mice with trehalose and 5 NTg mice with bicalutamide. Trehalose 
was administered orally in drinking water at 2% ad libitum, while bicalutamide was administered by 
subcutaneous injection (2mg/Kg) twice a week, both starting from 6 weeks of age until the age of 
sacrifice (20 weeks). 
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Figure 9  – Treatment validation - A) 
Chromatogram of NTg mouse spinal cord 
non-treated (analysis of three fragments 
red, green and blue line). B) 
Chromatogram of NTg mouse spinal cord 
treated with trehalose (analysis of three 
fragments red, green and blue line). C) 
Chromatogram of NTg mouse plasma 
non-treated (blu line) normalized on 
deuterated Bicalutamide (grey line). D) 
Chromatogram of NTg mouse spinal cord 
treated with bicalutamide (blu line) 
normalized on deuterated Bicalutamide 
(grey line). E) trehalose concentration 
(µg/g tissue) in the spinal cord of control 
or NTg mice treated with trehalose (n=5) 
(**p<0.01 by unpaired Student’s t test). 
E) bicalutamide concentration (µg/ml) in 
the plasma of control or NTg mice 
treated with bicalutamide (n=5) 
(***p<0.001 by unpaired Student’s t 
test). 
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The mass spectrometry analysis allowed us to detect the presence of trehalose in the spinal cord of 
treated mice, confirming us that trehalose is not completely metabolized by trehalase in the gut and 
is able to pass the blood-brain barrier.  Figure 9A shows the chromatogram of the spinal cord extract 
of control mice, with the peak of trehalose (at 3,15’); peaks of glucose (1,87’), sucrose (2,49’), maltose 
(3,04’) that partially hide the trehalose signal are also visible. After the treatment (Figure 9B), the 
concentration of trehalose increases but again, in the chromatogram, the trehalose peak is partially 
hide by maltose. Figure 9E shows that trehalose levels are tripled in the spinal cord of treated mice.  
The presence of trehalose in a central nervous system tissue, protected by the blood brain barrier, 
assure us that the compound reaches their target.  
The analysis of bicalutamide resulted to be simpler than that of trehalose. Indeed, using plasma 
collected from mice treated with bicalutamide, we can clearly detect the presence of the drug (Figure 
9C, 9D). The quantification of the bicalutamide levels is reported in Figure 9F.   
Moreover, we also measured blood sugar levels of mice at sacrifice to be sure that continuous high 
levels of the disaccharide trehalose does not cause alteration of glucose metabolism in mice, since in 
the SBMA patient metabolism problems and diabetes are often present (Figure 10). 
 
 
 
 
Figure 10 – Glycemia (mg/dL) of NTg mice (n=4), NTg mice treated with trehalose (n=5), KI AR113Q mice (n=7), KI AR113Q 
mice treated with trehalose at 24 weeks of age, and  NTg mice (n=5), NTg mice treated with trehalose (n=6), KI AR113Q 
mice (n=4), KI AR113Q (n=4) mice treated with trehalose at 52 weeks of age. Statistical analysis has been performed 
through two-way ANOVA analysis for group comparisons followed by Bonferroni post-hoc test. 
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Effect of trehalose or/and bicalutamide treatments on SBMA mice 
In the first set of experiment performed, we compared the effect of single treatments with trehalose 
or bicalutamide and of the combined treatment with the two drugs on KI AR113Q mice and their NTg 
littermates. Trehalose was administered orally in drinking water at 2% ad libitum, while bicalutamide 
was administered by subcutaneous injection (2mg/Kg) twice a week, both starting from 6 weeks of 
age until the age of sacrifice (52 weeks). 
As we did during mouse characterization, we analyzed the body mass of treated and non-treated mice.  
We did not find any variation in NTg or KI AR113Q treated mice (Figure 11A, 11B).  
Regarding the survival analysis, we observed that the treatment with trehalose or bicalutamide alone 
can increase the survival of KI AR113Q mice (Figure 11C); the survival increased from 39% to 56% with 
trehalose treatment, and to 58% with bicalutamide administration. The combined treatment 
increased the survival to 61%, and partially delayed disease progression, even if this result is not 
statistically significant. 
 
  
Figure 11 – Effects of trehalose and/or bicalutamide treatment - A) Body mass (mean ± SEM) reported by age of NTg mice 
(green line, n=14), NTg mice treated with trehalose (blue line, n=15), NTg mice treated with bicalutamide (purple line, n=8), 
NTg mice treated with trehalose and bicalutamide (orange line, n=12); B) Body mass (mean ± SEM) reported by age of KI 
AR113Q mice (red line, n=17), KI AR113Q mice treated with trehalose (blue line, n=18), KI AR113Q mice treated with 
bicalutamide (purple line, n=18), KI AR113Q mice treated with trehalose and bicalutamide (orange line, n=17); C) Kaplan-
Mayer survival curve of NTg mice (green line, n=14), KI AR113Q mice (red line, n=17), KI AR113Q mice treated with 
trehalose (blue line, n=18), KI AR113Q mice treated with bicalutamide (purple line, n=18), KI AR113Q mice treated with 
trehalose and bicalutamide (orange line, n=17) until 52 weeks of age. 
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Then, we measured: a) the forelimb skeletal muscle strength performing grip strength analysis, and b) 
motor coordination taking advantage of rotarod test, on NTg and AR113Q mice during the treatments. 
Mice were trained for test execution starting at 8 weeks of age. We weekly collected behavioral data 
starting from 10 weeks of age, until the age of sacrifice. Regarding the grip strength test, we did not 
observe any positive effect after our treatments, both alone or combined, in KI AR113Q mice (Figure 
12C). Nevertheless, we noticed a faster decline of performance in mice treated with bicalutamide 
alone or combined with trehalose both in NTg and SBMA mice (Figure 12A, 12C). Probably, this 
unexpected effect depends on the anti-anabolic effect of bicalutamide. Indeed, we administrated the 
anti-androgenic compound, that has also anti-anabolic side effects, starting from 6 weeks of age. At 
this age, mice are post-pubertal, perfectly able to reproduce, but their muscle development is not fully 
completed. 
About motor coordination, measured by rotarod, we did not observe the negative effect of 
bicalutamide find in grip strength test in NTg mice (Figure 12D), strengthening the theory of the 
detrimental anti-anabolic action on muscle; indeed, rotarod test can give information not only on the 
muscle health but also on the integrity of the sensory nervous system.  Rotarod test analysis, indicated 
a great increase of AR113Q mice performance after trehalose treatment alone: the performance of 
these mice was comparable to that of NTg mice (Figure 12D). 
 
Figure 12 – Motor behavioral effects of KI ARQ113 mouse treatments - A) Forelimb grip strength (mean ± SEM) by age of 
NTg mice (green line, n=14), NTg mice treated with trehalose (blue line, n=15), NTg mice treated with bicalutamide (purple 
line, n=8), NTg mice treated with trehalose and bicalutamide (orange line, n=12) evaluated weekly beginning at 10 weeks of 
age until the age of sacrifice (52 weeks). B) Rotarod test (mean ± SEM) by age of NTg mice (green line, n=14), NTg mice 
treated with trehalose (blue line, n=15), NTg mice treated with bicalutamide (purple line, n=8), NTg mice treated with 
trehalose and bicalutamide (orange line, n=12) evaluated weekly beginning at 10 weeks of age until the age of sacrifice (52 
weeks) C) Forelimb grip strength (mean ± SEM) by age of KI AR113Q mice (red line, n=17), KI AR113Q mice treated with 
trehalose (blue line, n=18), KI AR113Q mice treated with bicalutamide (purple line, n=18), KI AR113Q mice treated with 
trehalose and bicalutamide (orange line, n=17) evaluated weekly beginning at 10 weeks of age until the age of sacrifice (52 
weeks). D) Rotarod test (mean ± SEM) by age of KI AR113Q mice (red line, n=17), KI AR113Q mice treated with trehalose 
(blue line, n=18), KI AR113Q mice treated with bicalutamide (purple line, n=18), KI AR113Q mice treated with trehalose and 
bicalutamide (orange line, n=17) evaluated weekly beginning at 10 weeks of age until the age of sacrifice (52 weeks).  
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To better clarify the possible role of our treatments, in particular with bicalutamide alone or with 
trehalose, on the loss of muscle strength, we decided to create a second group of mice and to treat 
them starting from 10 weeks of age instead of 6, trying to avoid the anti-anabolic effect of 
antiandrogen compound. We observed that all NTg treated mice preserve their strength and motor 
coordination (Figure 13A, 13B). The strength of KI AR113Q mice resulted to be higher after the 
treatment with bicalutamide alone or with trehalose. Also, the performance at the rotarod test 
showed an increase in all groups of treated mice respect to untreated KI AR113Q mice (Figure 13C, 
13D).  
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Figure 13 – Effects of delayed bicalutamed treatment on mouse motor behavior - A) Forelimb grip strength (mean ± SEM) 
by age of NTg mice (green line, n=14), NTg mice treated with trehalose (blue line, n=5), or bicalutamide (purple line, n=5), or 
trehalose and bicalutamide (orange line, n=5)  evaluated weekly beginning at 10 weeks until 24 weeks. B) Rotarod test 
(mean ± SEM) by age of NTg mice (green line, n=14), NTg mice treated with trehalose (blue line, n=5), or bicalutamide 
(purple line, n=5), or trehalose and bicalutamide (orange line, n=5) evaluated weekly beginning at 10 weeks until 24 weeks. 
C) Forelimb grip strength (mean ± SEM) by age of KI AR113Q mice (red line, n=17), KI AR113Q mice treated with trehalose 
(blue line, n=5), or bicalutamide (purple line, n=5), or trehalose and Bicalutamide (orange line, n=5) evaluated weekly 
beginning at 10 weeks until 24 weeks. D) Rotarod test (mean ± SEM) by age of KI AR113Q mice (red line, n=17), KI AR113Q 
mice treated with trehalose (blue line, n=5), or bicalutamide (purple line, n=5), or trehalose and bicalutamide (orange line, 
n=5) evaluated weekly beginning at 10 weeks until 24 weeks. Bicalutamide was administered from 10 weeks of age, while 
trehalose from 6 weeks of age. 
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Morphological and biochemical analysis of skeletal muscle 
To elucidate whether the treatments with trehalose and bicalutamide have an impact on the 
morphological and biochemical markers, we decided first to focus our attention on muscle of our mice. 
This part of the studies was performed in collaboration with the group of Prof. Vercelli of the 
University of Turin 
 
.  
 
 
  
Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post-
hoc test. D) Analysis of gastrocnemius muscles centralized nuclei from KI AR113Q (red) mice, KI AR113Q treated with 
trehalose (blu), KI AR113Q treated with bicalutamide (purple) and KI AR113Q treated with trehalose and bicalutamide 
(orange) at 24 (symptomatic stage). Neurolucida analysis on a section of 40 µm. Each bar represents the mean   SEM 
of four independent replicates. Statistical analysis has been performed through tow-way ANOVA for group comparisons 
followed by Bonferroni post-hoc test. (E) Muscle fiber size distribution analysis by percentage of fiber from 
gastrocnemius KI AR113Q (red) mice, KI AR113Q treated with trehalose (blu), KI AR113Q treated with bicalutamide 
(purple) and KI AR113Q treated with trehalose and bicalutamide (orange) at 24 (symptomatic stage). 
 
E 
A B 
C 
D 
E 
Figure 14 – Effect of trehalose and bicalutamide 
treatment on mouse muscle morphology – A) The 
morphology of the muscles (gastrocnemius) is 
highlighted by hematoxylin/eosin staining. Scale bar = 
100 μm (right panels) 50 μm (left panels). Centralized 
nuclei are marked with arrows (left panels). B, C) 
Analysis of gastrocnemius muscle fiber size (B maximum 
Feret diameter, C minimum Feret diameter) from KI 
AR113Q (red) mice, KI AR113Q treated with trehalose 
(blu), KI AR113Q treated with bicalutamide (purple) and 
KI AR113Q treated with trehalose and bicalutamide 
(orange) at 24 (symptomatic stage). Neurolucida 
analysis on a section of 40 µm.  
Each bar rep esents the mean  s.e.m f four 
ind pendent replicates.  
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The treatment with trehalose induced an increase of the muscle fiber size, not appreciable analyzing 
only maximum or minimum Feret diameter (Figure 14B, 14C), but observing muscle fiber distribution 
graphic (Figure 14E), where the percentage of big fiber resulted to be higher in the muscle of mice 
treated with trehalose than that in untreated mice. This increase of fiber size was greater when the 
double treatment with trehalose and bicalutamide was administrated to SBMA mice. We did not find 
variation counting the number of centralized nuclei, usually associated to muscle regeneration (Figure 
14A, 14D).  
To determine whether changes in gene expression, a quantitative real-time RT-PCR was used to 
measure levels of myogenin, acetylcholine receptor α-subunit, myogenic differentiation antigen also 
known as MyoD and Pax7. Surprising none of these markers showed variation after any treatment 
both at symptomatic stage (24 weeks) and end stage (52 weeks) (Figure 15).  
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Figure 15 – Expression of 
muscle marker doesn’t 
change - RT-qPCR analyses of 
the mRNA levels of AchR (A, 
B), MyoD (C, D), MyoG (E, F), 
Pax7(G, H) performed on total 
RNA extracted from 
gastrocnemius of male KI 
AR113Q (red),  KI AR113Q 
treated with trehalose (blu), 
or bicalutamide (purple) or 
trehalose and bicalutamide 
(orange) at 24 (symptomatic 
stage) or 52 (end stage) 
weeks of age. 
Data have been normalized to 
RpLP0 mRNA, expressed 
relative to the levels 
determined in NTg mice at 24 
weeks of age, which are taken 
as internal reference, and 
expressed as fold changes. 
Each bar represents the mean 
 s.e.m. of five independent 
replicates. 
Statistical analysis has been 
performed through two-way 
ANOVA for group 
comparisons followed by 
Bonferroni post-hoc test. 
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Therefore, we analyzed several markers with the aim to find variation which could correlate with the 
positive data obtained with rotarod test and with survival analysis. One of these markers is Pgc1α, a 
key factor for mitochondria biogenesis. We found that its mRNA expression is increased 2-3 times 
after mice treatment with both trehalose and bicalutamide, at the end-stage of the disease (52 
weeks) (Figure 16B). 
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Figure 16 - PGC1α mRNA is induced by the combined treatment with trehalose and bicalutamide - RT-qPCR analyses of the 
mRNA levels of PGC1α (A, B) performed on total RNA extracted from gastrocnemius of male KI AR113Q (red),  or trehalose 
(blu), or bicalutamide (purple), or trehalose and bicalutamide (orange) at 24 (symptomatic stage) or 52 (end stage) weeks 
of age. Data have been normalized to RpLP0 mRNA, expressed relative to the levels determined in NTg mice at 24 weeks of 
age, which are taken as internal reference, and expressed as fold changes. Each bar represents the mean  sem of five 
independent replicates (*p<0.05). Statistical analysis has been performed through two-way ANOVA for group comparisons 
followed by Bonferroni post-hoc test. 
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Analysis of the autophagic pathway in KI AR113Q mice  
Since our goal was to induce and take advantage of autophagy with trehalose and bicalutamide we 
decided to measure changes in the expression of autophagic markers, in skeletal muscle of 
symptomatic and end stage AR113Q male mice. It has already been reported 181 that the autophagy 
master regulator gene product TFEB is up-regulated in these mice when symptoms appear, and TFEB 
controls the expression of a series of genes whose protein products are involved in the autophagy and 
lysosome dynamics.    
Here, we analyzed the expression of some genes encoding proteins which are essential for autophagy 
initiation and are critical markers for the autophagic process. Beclin-1 (the ATG6 ortholog, which 
regulates and associates to Vps34 to induce autophagy) is critical for autophagosome assembly, 
p62/SQSTM1 (which recognizes ubiquitinated protein for their insertion into autophagosomes) is a 
TFEB regulated autophagy marker, HSPB8, that we already demonstrated is one of the key protein 
involved in the autophagic removal of misfolded proteins 182, and his co-chaperone BAG3 (Figure 17). 
Beclin-1 mRNA expression is the only one that changed, showing a reduction after the treatment with 
bicalutamide alone or with trehalose at symptomatic stage (24 weeks) (Figure 17E). 
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Figure 17- Expression of 
autophagic markers in 
muscle of trehalose and/or 
bicalutamide treated 
mice.- RT-qPCR analyses of 
the mRNA levels of BAG3 
(A, B), p62/SQSTM1 (C, D), 
Beclin1 (E, F), HSPB8 (G, H) 
performed on total RNA 
extracted from 
gastrocnemius of male KI 
AR113Q (red),  KI AR113Q 
treated with trehalose 
(blu), or bicalutamide 
(purple), or trehalose and 
bicalutamide (orange) at 
24 (symptomatic stage) or 
52 (end stage) weeks of 
age. 
Data have been 
normalized to Rplp0 
mRNA, expressed relative 
to the levels determined in 
NTg mice at 24 weeks of 
age, which are taken as 
internal reference, and 
expressed as fold changes. 
Each bar represents the 
mean  s.e.m. of five 
independent replicates 
(*p<0.05). 
Statistical analysis has 
been performed through 
two-way ANOVA for group 
comparisons followed by 
Bonferroni post-hoc test. 
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Discussion 
Spinal and bulbar muscular atrophy (SBMA) or Kennedy’s disease is an X-linked motor neuron disease 
characterized by lower motor neuron degeneration in anterior horns of the spinal cord and in 
brainstem 6 , involving also dorsal root ganglia neurons causing motor and sensory disturbances 10. 
The loss of motor neurons results in atrophy of bulbar, limb and facial muscle 7. 
Recent evidence seems to suggest that muscle atrophy is not only a simple consequence of 
denervation induced by loss of motor neuron and their trophic effects, but also depends on direct 
damage occurring in muscle cells 183. Kennedy’s disease is linked to an expanded CAG triplet-repeat 
sequence in the androgen receptor gene. Consequently,  the gene is translated into an elongated poly-
glutamine tract in the androgen receptor protein, found longer than 38 glutamine in patients 6. 
The study of SBMA presents two important advantages; first, the profound knowledge of androgen 
receptor structure, mechanisms and function, and, second, the mutated AR toxicity become evident 
only after the interaction between androgen receptor and testosterone. Indeed, Kennedy’s disease 
occurs only in men and surgical or chemical  castration ameliorates the phenotype in SBMA mice 
models 38,74.  
The absence of testosterone lead ARpolyQ to localize in the cytoplasm where it forms a multi-
heteromeric complex with chaperones preventing AR to exert its toxic effect in the nucleus. This 
aggregation process, initially may result to be protective, but at later stages lead to sequester also 
other proteins altering the physiological function of neurons and becoming toxic 42,184. Based on this 
evidence, the key strategies to treat SBMA may be the prevention of the interaction between AR and 
testosterone, and the enhancement of the androgen receptor aggregates degradation.  
To reach this goal we have already tested in vitro two different compounds obtaining promising 
results, therefore we decided to start a trial on a mouse model of the pathology. 
We choose a knock-in mouse expressing a humanized AR in which the coding region of mouse exon 1 
is exchanged for human sequence. Expression of the AR gene is under the control of the endogenous 
mouse regulatory machinery, resulting in expression levels similar to WT allele 75, to better mimic the 
real progression. 
Our first analyses have been focused on the characterization of the animal model. We found 
symptoms of muscular atrophy, as already demonstrated by Yu in 201275. Our analysis showed a 
mouse smaller than non-transgenic littermates, weaker and mainly with lower motor performance. 
Indeed, it is known that AR aggregates are present also in dorsal root ganglion neurons compromising 
the sensory pathways. In fact, it is also known that patients complain an alteration of their sensory 
performance5. In accordance with this alteration we reported a lower performance of SBMA mice at 
the rotarod test that is known to reflect the coordination between motor with sensory inputs. 
PolyQ AR is sequestered into aggregates and the great part of the receptor can’t reach the nucleus 
and interact with the target genes. This gives rise to a second category of symptoms in SBMA patient 
characterized by endocrine alterations leading to gynecomastia, infertility and hypogonadism 65. In KI 
AR113Q models we founded a huge reduction of the weight of seminal vesicles suggesting a low AR 
activity, as in SBMA patients. 
Kennedy’s disease, unlike other neurodegenerative disease, is a pathology with a very slow rate of 
progression, leading at the end to the death of patients. Our model represents also this feature of the 
pathology, with a mortality of 61% of the animals before one year of life. The cause of death of the 
animals that die earlier is a block of urinary system. Urinary system alterations and deficits are also 
present in patients, leading to the need for catheterization.  
We analyzed the mRNA expression of muscle atrophy markers; unfortunately, we were not able to 
find any variation in MyoG (myogenin) or MyoD gene expression, two proteins usually associated with 
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muscle differentiation; the expression of Pax7 was found to be increased both at 24 and 52 weeks old 
mice respect to NTg mice. Interestingly, an elevated Pax7 mRNA expression is indicative of an attempt 
to regenerate after muscle injury. Together with the observation of elevated levels of AchR, these data 
confirm alteration in muscle and possibly an association to denervation in skeletal muscle of AR113Q 
mice. To strengthen this evidence, in histological analysis we also observed that functional and 
molecular alterations are accompanied by morphological changes such as groups of angulated fiber, 
mild atrophic fibers which are once again indicative of muscle damage. All this evidence and the data 
reported in literature on KI AR113Q 75,184 mice confirm its reliability as disease model.  
The second step of our experiment was to analyze the effects of the treatment with trehalose or 
bicalutamide alone or in combination. 
Regarding the treatment with trehalose, it is known that enterocytes express the enzyme trehalase 
which is able to metabolize trehalose into glucose139. For this reason, we tried to measure the levels 
of trehalose into the blood. Furthermore, trying to demonstrate that the absorbed trehalose can pass 
the brain blood barrier we evaluated the levels of trehalose into the spinal cord through mass 
spectrometry analysis. The set-up of plasma analysis has been very difficult because trehalose is a 
disaccharide which may be confused with other sugars such as maltose or sucrose which are obvious 
“contaminants” in the plasma of mice. The analysis was easier in the spinal cord. In this tissue, we 
found higher trehalose concentration in treated mice than in untreated mice, confirming that the oral 
administration of trehalose we performed (2% in drinking water ad libitum) is effective to overcome 
the degradation by intestinal trehalase and the blood brain barrier. Also, the treatment with 
bicalutamide was effective since its blood concentration reached pharmacological active levels. 
Furthermore, we also collected glycemia data from all trehalose treated mice to confirm the absence 
of metabolism alteration since it is known from literature that patients are also characterized by 
metabolism alteration, diabetes and metabolic syndrome like symptoms. We did not find any 
alteration in glycemia levels at 24 weeks of age.  
After having characterized KIAR113Q mouse model and controlled the efficacy of the route of 
administration, we start to treat and analyze mice observing their behavior. Surprisingly trehalose 
alone proved to drastically increase the performance on rotarod of SBMA mice, while the treatment 
with bicalutamide alone or combined with trehalose worsened mice motor performance and muscle 
strength, also of wild type mice. Therefore, suspecting an anti-anabolic effect of the antiandrogen 
bicalutamide on muscle of mice not completely developed, we decided to treat a second group of 
mice starting at 10 weeks of age instead of 6. In the first set of experiment, we started to treat animals 
with bicalutamide at 6 weeks of age. At this age, mice can reproduce but they are still in the middle of 
their development. The new age of beginning of treatment clearly showed better result than that 
obtained with the first group of treated mice. Indeed, while results obtained with grip strength meter 
were highly variable, data obtained with rotarod test indicated that bicalutamide treatment (alone or 
in combination) can ameliorates KI ARQ113 mouse motor performance to comparable levels of NTg 
mice. 
The result previously obtained in vitro 87 showed a huge effect of the combined treatment, suggesting 
a synergic effect of bicalutamide and trehalose administered together. We cannot observe any 
synergic effect at rotarod test, because trehalose or bicalutamide single treated mice already reached 
the performance of untreated wild type mice. However, analyzing survival data, we found an increase 
of survival for all treated group, comparable between both single and combined treatments. 
Furthermore, the group treated with both trehalose and bicalutamide showed also a delay of disease 
progression, suggesting, as in vitro, a synergic effect.   
At the moment, we focused our attention and analysis on gastrocnemius muscle, to find a possible 
molecular mechanism changed by treatments. The histological analyses  did not show any significant 
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difference in maximum and minimum fiber diameter, but the fiber size distribution analysis suggested 
a greater increase of fiber size in mice treated with both compound than single treatments. 
Unfortunately, we did not find any variation in mRNA expression of markers of muscle regeneration, 
differentiation or degeneration. About autophagy, we found a reduction in beclin1 mRNA expression 
at 24 weeks of age in presence of bicalutamide alone or combined with trehalose. This variation may 
suggest a reduction of autophagy induction, probably because of lower quantity of aggregate to 
degrade, since trehalose induced clearance has already reduced the AR aggregates. This is only an 
explanation that we must prove since at 52 week of age we don’t observe again this reduction.  
We also analyzed several markers of muscle metabolism and, interestingly, we found an increase of 
Pgc1α mRNA expression, which regulates energy metabolism and mitochondria biogenesis and 
function. Also, in this case we observed an increase only after the combined treatment. 
In the future, we want to focus our attention on mitochondria analysis to confirm this data and clarify 
if and how an increase of Pgc1α may lead to an amelioration of the motor behavior.  
Moreover, in the future we want to analyze dorsal root ganglia trying to find molecular changes 
involved in the enhancement of motor coordination after mice treatment.  
Another key step will be the analysis of androgen receptor expression, aggregation, and distribution 
in different tissue, from muscle to spinal cord, to better understand the AR behavior after trehalose, 
bicalutamide and their combined treatment.  
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Introduction 
Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that affects motor neurons in the 
brain, brainstem and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal 
muscles 185.  
The onset age of familiar forms (fALS) is a decade earlier than the onset age of sporadic forms (sALS), 
which have an age-dependent incidence. The incidence of sALS is 1.89 people per 100,000/year and 
the prevalence is 5.2 people per 100,000. The median age of onset is approximately 60 years. The 
median survival ranges between 3 and 5 years from symptom onset, which varies between 55 and 65 
years with a median age of 64 years 186. Onset before age 30, called juvenile sporadic onset, is only 
found in 5% of cases. The life-time risk of sALS by the age of 70 has been accurately estimated to be 1 
in 400. Another important consideration is that many studies have demonstrated that a slight excess 
of males are affected with sALS compared to females, with a male/female ratio of approximately 1.5: 
1 123. 
Interestingly, despite ALS cases are widespread, in the Western Pacific ALS prevalence is 50–100 times 
higher than elsewhere in the world. The population of the Chamorro people of Guam and Marianas is 
very well known. One of the first studies performed in this population in 1957 described a genetic 
origin of ALS associated with Parkinsonism and dementia independent of environmental changes 187. 
ALS is a complex disease characterized by several different symptoms and phenotypic heterogeneity. 
New theory ad results suggest that ALS phenotype could be depend from different disorder that lead 
to comparable end stage symptoms188. More than half of the ALS patients also present cognitive 
disorder, and some of them show characteristic features, such as progressive social, behavioral and/or 
language dysfunction, of frontotemporal dementia or frontotemporal lobar degeneration.  
The majority of ALS is sporadic with unknown etiology, while 10% is familial with dominant 
inheritance. Sporadic and familial ALS are clinically indistinguishable and share several pathogenic 
pathways 189. Several ALS-related genes are known; however, genetic mutations do not explain the 
existence of the large number of idiopathic cases. Interestingly, sporadic ALS has been linked to many 
environmental factors, including heavy metal toxicity and exposure to pesticides and fertilizers. 
A simple view would predict that genetic variation and environmental exposure contribute to ALS, yet 
it is also likely that environmental exposures influence epigenetic mechanisms, influencing gene 
expression, to promote the onset and progression of ALS 190.  
Pathogenesis 
ALS is considered a multifactorial disease, therefore caused by several alterations. Indeed, 
modification in RNA processing,  apoptosis, mitochondrial dysfunction, fragmentation of the Golgi 
apparatus, and metal imbalances, alterations to the motor neuron microenvironment, including 
accumulation of protein aggregates and glutamate excitotoxicity are observed in patients191,192. 
 One of the first event observed is a molecular alteration in the neuro muscular junction, before that 
neurodegeneration begin. In both ALS and FTD are present alterations in neurotransmitter release. 
Moreover, often ALS neurons are characterized by the presence of inclusions and ubiquitinated 
protein aggregates193. Furthermore, RNA processing disruptions is also a feature of ALS, inducing 
alteration in RNA maturation, regulation and also in exon splicing.   Despite 90% of ALS cases are 
 Chapter 2 - Introduction 
55 
 
sporadic, in the past years attention was focused on familiar forms of disease, to find a common 
mechanism. Were found some mutation in gene, usually involved in RNA maturation. The most diffuse 
mutation  include 20% of SOD1 gene mutation and approximately 5% have mutations in the TARDBP 
gene (TAR DNA binding-protein, TDP-43) 194,195. 
Other genes, such as fusion in malignant liposarcoma/translocated in liposarcoma (FUS/TLS), 
angiogenin (ANG), the vesicle associated membrane protein-associated protein B (VAPB), senataxin 
(SETX), dynactin, and the most recently discovered gene, a hexanucleotide repeat expansion in 
C9ORF72, have been identified in ALS patients 196. C9ORF72 gene has been defined as the most 
common mutation in SALS and FALS, representing up to 6% and up to 40% respectively. Other 
candidate genes that have been described in ALS genome association studies, such as neurofilament, 
peripherin, vascular endothelial growth factor (VEGF), angiogenin, survival motor neuron (SMN), and 
hemochromatosis (HFE) 197. 
 
 
 
 
 
The first mutation discovered to be involved in ALS is a mutation in the superoxide dismutase 1 (SOD1) 
gene are present in 20% of fALS cases. For this reason  SOD1 mutant form are widely use to generate 
in vivo and in vitro model and study disease features198. SOD1 in a physiological condition can be found 
in the intermembrane of mitochondria. It’s an antioxidant protein with the role of converts superoxide 
radicals to hydrogen peroxide. More than 170 mutation were found on SOD1 gene, and the majority 
lead to an unknown gain of toxic function199. Toxicity of mutant SOD1 may also depend on a loss of 
function. Indeed, low level of active SOD1 can’t degrade all superoxide radicals. Accumulation of 
Figure 18 -Schematic representation of the different molecular pathways altered in amyotrophic lateral sclerosis. Although 
the trigger for neurodegeneration remains unknown, all these deregulated mechanisms prompt motor neuron death 
(Calvo 2014). 
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radicals lead to an oxidative stress that induce neurodegeneration200. Moreover mutant forms of SOD1 
seems to has prion-like properties and sequester in aggregate also native forms of the protein, and 
also induce wild type SOD1 to misfolding201.  Additionally, mutations in SOD1 cause misfolding of the 
nascent SOD1 polypeptide, promoting also the formation of aggregates, especially during oxidative 
stress 202.  
TAR DNA-binding protein 43 (TDP-43) and RNA binding protein FUS are members of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) family. FUS and TDP-43 are both involved in RNA 
maturation and transport. They are also involved in transcription, splicing and are considered a shuttle 
between cytoplasm and nucleus193. Were found more than 40 mutations in the gene coding for TDP-
43 involved in ALS203. In the inclusion observed in ALS and FTD patient often is detectable the C-
terminal region of TDP-43, the same region where almost all mutation TDP-43 are described204. ALS-
associated mutations in FUS occur within a linkage region on chromosome 16 and affect the protein 
C-terminus. FUS mutations account for 5% of familial ALS 205, and most patients with FUS associated 
ALS have FUS-immunoreactivity cytoplasmic inclusions but the typical phosphorylated TDP-43 positive 
inclusions are absent 206. FUS mutation can be linked TDP-43 alteration or share the pathway, inducing 
axonal defects , neurodegeneration sequestering in inclusions also the survival of motor neuron 
protein (SMN) 207. This protein is necessary for the formation of spliceosome. Low level of SMN in 
children induce muscular atrophy and ALS like symptoms. In present of mutation, FUS and TDP-43 
can’t interact with their target, and they also can’t regulate RNA metabolism.  Therefore, in this 
pathological condition both FUS and TDP-43 association with RNA may lead to an abnormal 
phosphorylation, ubiquitination and aggregation of proteins, as well as aberrant cellular functions, 
and formation of stress granules 208. Stress granules are composed of repressed translation complexes, 
where mRNA-binding proteins consolidate stalled mRNA. Notably, in most patients with familial ALS, 
TARDBP is not mutated, yet TDP-43 aggregates may be present (except in cases caused by SOD1 or 
FUS mutations), disrupting RNA processing and could be one trigger of degeneration 209. 
The most common genetic cause of ALS and FTD is linked to chromosome 9p21, where a founder 
haplotype occurs in the so-called ALS–FTD locus, including the chromosome 9 open reading frame 72 
(C9orf72) gene, and is associated with autosomal dominant inheritance 210. In the affected haplotype, 
expansions in a large non-coding hexanucleotide (GGGGCC) repeat in the first intron of C9orf72 can 
reach hundreds of copies in patients presenting an FTD/ALS 211. The exact mechanism by which the 
C9orf72 repeat expansion triggers disease is unclear, and several possible explanations currently exist 
212. The main mechanism suggest that the repeat expansion could potentially alter the expression of 
the mutant allele since the mRNA expression of C9orf72 has been observed reduced in ALS patients 
suggesting a kind of loss of function 196.  
 
Despite it is known that a genetical predisposition could be crucial for ALS development other 
pathogenic factors are likely to be environmentally determined 213. Moreover, seems that sporadic 
form of ALS may depend also on inflammatory cytokines, diet, toxic exposures and other factors that 
together could induce the neurodegeneration, usually interfering or inducing epigenetic changes 214.  
Accumulation of mercury, a neurotoxin that inhibits SOD1 activity, in motor neurons damages the 
cytoskeletal components and impairs axonal transport, causing phenotypes similar to ALS215. Also, 
high level of aluminum corelate with motor neuron disease like symptoms. For instance, high level of 
aluminum is present in the drinking water in western Pacific region, where are reported many case of 
sALS. Nevertheless, it is known than high metal levels alone can’t induce ALS pathogenesis216. ALS risk 
has also been linked with exposure to fertilizers, insecticides and herbicides. Occupational and home 
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exposure to pesticides and fertilizers tend to be higher in patients with ALS than in controls and these 
exposures are also associated with increased risk for developing Parkinson disease (PD) 217. Many 
studies suggest also cigarette smoking contribution in ALS development, and in a faster disease 
progression. Moreover, also head injuries or physical trauma seems to correlate with higher risk of 
ALS 218.  
Epigenetics, defined as structural adaptation of chromosomal regions to register signal, or perpetuate 
altered activity states, represents a potential convergence between genetic predisposition and 
environmental exposures 219. Epigenetic is important for neuronal adaptation, plasticity and 
development and respond to stimuli beyond the inherited genetic outline. The possibility to switch on 
or switch off epigenetic mechanism, make it a possible target for ALS therapy. Epigenetic mechanisms 
include DNA methylation, histone remodeling, RNA editing, and expression of noncoding RNAs such 
as microRNAs (miRNAs) 220. 
DNA methylation involves the post-transcriptional covalent addition of a methyl group to cytosine 
residues in DNA, leading to 5-methylcytosine formation. This modification can induce variation in the 
interaction between DNA and the chromatin protein and also change the transcription rates of the 
target gene 221. Usually DNA I methylated in its regulatory region, for example element CpG 
dinucleotides, which are clustered in CpG islands or CpG island shores 222. Methylation of DNA may be 
a power candidate for a possible therapy because of its nature of stable and reversible bind. 
Supporting a role for reversible DNA methylation in ALS, DNMT3A, the DNA-(cytosine-5)-
methyltransferase (DNMT) enzyme 3A, is present in the brain and spinal cord of patients with ALS, 
and its overexpression prompts cell death in motor-neuron-like cells in vitro 223. Moreover, genome 
wide methylation arrays have revealed hypomethylation of the ALS-related gene.  
DNA methylation may also be a promising approach in ALS form characterized by C9orf72 mutation, 
since the hexanucleotide repeat expansion usually depend on a CpG islands hypermethylation220.  
Indeed, in some studies hypermethylation of CpG islands near C9orf72 gene is associated with the 
presence of the repeat expansion in tissue samples from patients with ALS. Modification in DNA 
methylomes, isn’t a feature only of ALS, but is show also in many other neurodegenerative disease, 
especially if involving nucleotide repeat expansion, including spinocerebellar ataxia type 1, Friedreich 
ataxia, fragile X syndrome, myotonic dystrophy, PD and Alzheimer disease (AD). Together, these 
findings support the hypothesis that altered DNA methylation contributes to neurodegeneration in 
patients with ALS 224.A second epigenetic mechanism is represented by post-translational 
modifications of H3 and H4 histone tails via acetylation and methylation allowing chromatin to 
dynamically change from a highly packaged, transcriptionally inactive, conformation 
(heterochromatin) to a transcriptionally active state (euchromatin) 225. The histone acetyltransferases 
promote acetylation of histone tails and so also transcription, while histone deacetylases remove 
acetylation, silencing the gene. The methyltransferases promote histone methylation. It is reported in 
literature that overexpression of histone deacetylases may have a detrimental role in nervous system, 
indeed low levels of histone acetylation are often observed in neurodegenerative disease models226. 
For instance, high level of  histone deacetylases 3 causes degeneration of rat neurons and cultured 
HT22 hippocampal cells and a post mortem analysis reported an increase in histone deacetylases 2 
mRNA and a reduction in HDAC11 mRNA in spinal cord and brain tissue from patients with ALS 227. 
Thus, DNA methylation and histone modifications might be important therapeutic targets. 
Several patients present also modification in RNA editing, another epigenetic mechanism. This system 
occur to change the some RNA nucleotide sequence, obtaining a sequence different from the original 
DNA228.  The most common change in patients with ALS is the deamination of adenosine to inosine. 
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This modification might underlie the excitotoxic effects of variants of the AMPA (alpha-amino-3- 
hydroxy- 5-methyl-4-isoxazolepropionate) receptor in ALS, linked to excitotoxity theory of glutamate 
229.   
Also, miRNA may have an important part in ALS development, since in several disease differences in 
miRNA expression have been observed between normal and pathological cells or tissue, and miRNA 
expression seems to change during the pathogenetic progression. miRNAs are small, more or less 22 
nucleotides, noncoding RNA highly conserved. miRNA are involved in regulation of several hundred 
targets via RNA-dependent posttranscriptional silencing mechanisms and mRNAs, and their 
expression can be regulated by other miRNAs230. miRNAs undergo a detailed maturation process that 
occurs in the nucleus and cytoplasm 231. Thus, the miRNA-mediated alteration of biological pathways 
could partially explain complexity of ALS and other diseases 232. In neurodegenerative pathologies, the 
implications of miRNA dysregulation have not been fully elucidated, and it is crucial to determine 
whether dysregulation occurs via transcriptional or post-transcriptional mechanisms, or both.  
Alteration in miRNA biogenesis may have some important consequence and development of different 
diseases symptoms. For example, it is known that a loss of function in the protein Dicer1, an extremely 
important factor in miRNAs maturation, in rodent motor neurons lead to a SMA like phenotype233. 
Likewise, low activity of TDP-43 its lower interaction with Drosha-containing protein complexes, 
another main character in the miRNA maturation, lead to alteration in miRNA processing234. 
 
Since miRNA have an important role in many pathway, recently several studies focus their attention 
on miRNA expression. Interestingly data about alteration in miRNAs levels was obtained from patient 
biopsy.  For instance, miR-663a and miR-9-5p were exclusively downregulated in patients with FUS 
mutations and let-7b was altered in both FUS and C9orf72 mutation carriers. Overall, the prevalence 
of mostly downregulated TDP-43-binding miRNAs suggests that a general defect in RNA metabolism 
may be present in patients with ALS. Also decreases in miR-124a are seen in the spinal cord of mutant 
SOD1 mice, suggesting that dysregulated glutamate transport pathways probably contribute to the 
exacerbation of ALS pathology 235.  
Also, observation from skeletal muscle samples of patients are source of important information. 
Indeed, expression of miR-23a, miR-29b, miR-206, and miR-455 has been observed. miR-23a 
suppresses the activity of the peroxisome proliferator-activated receptor-γ co-activator (PGC)-1α, a 
protein involved in mitochondrial biogenesis and function, which might indicate that specific miRNAs 
represent therapeutic targets 236. Similarly, miR-206 is increased in skeletal muscles of patients with 
ALS and in symptomatic mutant SOD1 mice, possibly owing to the effects of denervation. The loss of 
miR-206 accelerates disease progression in mice, probably because of its involvement in skeletal 
muscle development, synaptic plasticity, neuromuscular junction regeneration, and nerve to muscle 
communication 236. 
Phenotype and symptoms 
Familiar and sporadic ALS patients are characterized by motor neurons degeneration, both upper, in 
the cerebral cortex, and lower in the anterior horn in the spinal cord. The mains clinical features are 
muscle weakness, usually until death because of respiratory failure 237. 
Median survival ranges from months to decades but is 19 months from diagnosis and 4/5 years from 
onset. The variability and overall rapid progression make it difficult to predict survival time or the 
timing of interventions 238.  
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ALS could have a limb-onset, characterized by younger patients, and usually milder symptoms of 
muscle dysfunction, higher breathing capacity, longer interval between symptom onset and diagnosis 
and longer survival than other classes of ALS239. In all ALS type loss of lower motor neurons lead to 
cramps, muscle atrophy, fasciculation and muscle weakness. Usually for the patient weakness result 
the most disabling features. Other symptoms are spasticity, hyperreflexia.   ALS is clinically 
heterogeneous even among family members harboring the same gene mutation; a single etiology can 
lead to numerous clinical syndromes. In addition to variable progression rate, primary and secondary 
motor neurons are differentially affected, onset occurs in different body regions, and cognitive as well 
as behavioral disturbances could be mutable.  
In the most of case, two-third of patients, the first symptoms occur in the limbs and usually only one 
arm or leg. Early features usually are weakness when lifting the arms, foot drop or difficult to walk. 
Bulbar- onset ALS, is characteristic of older patient than limb-onset. Often occur in women and carries 
a worse prognosis197. Primary symptoms are dysphagia, dysarthria and an atrophied fasciculating 
tongue, which usually lead to malnutrition and anarthria. Axial weakness can cause dropped head and 
kyphosis, which are associated with pain and poor balance. Eye movements are preserved in all type 
of ALS, until advanced stages 240. 
Frontotemporal dementia (FTD) occurs in approximately 15% of people with ALS. Primary progressive 
aphasia, semantic dementia and the behavioral variant are subtypes of FTD that affect executive 
function, language, judgment, personality, and behavior 240.  
It is reported that patient that present both ALS and FTD have a shorter survival241. Moreover, 
symptoms like as anxiety, depression could impair patient quality of life through poor sleep and 
appetite, while usually ALS patient are characterized by a rational approach the disease, and rates of 
depression seem to be lower than expected242.. Pain can occasionally result from involvement of 
sensory neurons, and frequently from contractures, immobility, inability to turn in bed, or bedsores. 
As the disease advances, shortness of breath occurs during simple tasks such as dressing and eating, 
and eventually at rest 243.  
Transforming growth factor β 
Transforming growth factor β (TGF β) isoforms (TGF β1, 2, and 3) are pleiotropic factors with important 
roles during embryonal development and in the regulation of tissue homeostasis 244. Overactivity of 
TGF β has been connected to diseases such as fibrotic conditions and malignancies 245.TGF β isoforms 
exert their cellular effects by binding to heterotetrameric complexes of type I and type II serine/ 
threonine kinase receptors. Upon formation of the receptor complexes, the constitutively active type 
II receptor phosphorylates and activates the type I receptor 246. The main pathway through TGF β exert 
its function, involved Smad family protein. Indeed, the primary substrate of TGFβ type I receptor for 
the phosphorylation are Smad2 and Smad3, although non-Smad pathways are also possible.  
Phosphorylated Smad2/3 can interact with the common partner Smad4, which are a sort of importin 
and can translocate in to the nucleus. Here, the complex Smad2/3 and Smad4 can cooperate with 
many transcription factors and regulate their target gene transcription among the genes that are 
induced by TGFβ stimulation is the inhibitory (I-) Smad7, which is involved in a negative feedback 
mechanism to inhibit TGFβ signaling 247.  
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TGFβ in motor neuron and muscle 
The three TGFβ isoforms are usually expressed by both neurons and glial cells, while TGFβ receptors 
can be find in all the central nervous system. The isoforms 2 and 3 is expressed mainly in astrocytes, 
whereas TGFβ 1 is present only in the choroid plexus and meninges. Moreover, immunohistochemical 
analysis have detected high present of TGFβ also in pyramidal neurons in the cortex and motor 
neurons in the brainstem and spinal cord. It is already known that TGFβ and its pathway have an 
important role in the survival of adult neurons248.  
For example, TGFβ 1 increased the survival and augmented choline acetyltransferase (ChAT) activity 
of rat primary motor neurons cultured on monolayers of cortical astrocytes. It is important to note 
that TGFβ has only a weak neurotrophic effect by itself, but strongly promotes motor neuron survival 
when administered with other growth factors such as fibroblast growth factor-2 8. TGFβ show also to 
play an important role in the growth of synapsis, release of neurotransmitter and neuron 
maintenance. In Aplysia, TGFβ 1 modulates synaptic functions via the induction of phosphorylation 
and the redistribution of the presynaptic protein synapsin and mediates long-term neuronal plasticity 
249. Taking advantage of TGFβ knockout mouse the role of TGFβ signals in central nervous system was 
exhaustively analyzed. In these mice, various part of the brain shows microgliosis, reduced synaptic 
density and at the end neuronal death. Moreover the brain shows an increased vulnerability to kainic 
acid toxicity250. Anyway, at the moment no information are available about motor neuron system in 
absence of TGFβ signaling251.  
Figure 19 - TGFβ binds to type I (TGFβRI) and type II (TGFβ RII) receptors. Ligand binding induces the formation of 
heteromeric complexes in which TGFβRII phosphorylates TGFβRI. Phosphorylated TGFβ RI then activates the receptor-
regulated Smad proteins (Smad2 and 3). Phosphorylated Smad2/3 (pSmad2/3) translocate into the nucleus, together with a 
common-partner Smad (Smad4), and regulate the transcription of target genes such as p21 and p15 (Katsuno 2011) 
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TGFβ signaling is also known to regulate the functions of the neuromuscular junction (NMJ). The motor 
nerve terminals at the NMJ contain TGFβ receptors, and TGFβ 2 increases the postsynaptic response 
through the regulation of presynaptic quantal size 252. Schwann cells express TGFβ 1, which is both 
sufficient and necessary to promote synaptogenesis at the NMJ.  
The TGFβ-Smad2/3 pathway functions virtually in all cell types, including muscle. TGFβ -signaling has 
negative effects on muscle growth 253. Myostatin, a member of the TGFβ superfamily, has gained 
attention as a potential therapeutic target for myopathies because genetic deletion of this factor 
results in increased muscle volume 254.  
TGFβ in SBMA 
In SBMA patient pathogenic AR interacts with the expression of TGFβRII, reducing the expression of 
TGFβRII in spinal motor neurons of SBMA transgenic mice (AR 97Q) before the onset of the 
neuromuscular symptoms255. Moreover, also the activity of pSmad2/3 is inhibited in the motor 
neurons of SBMA mice. It is known, that pSmad2/3 is particularly decreased in the motor neurons 
showing nuclear accumulation of pathogenic AR in SBMA models and in autopsied patient. In vitro 
experiments show that low level of TGFβRII, induced by siRNA, decreased the levels of nuclear 
pSmad2/3 while overexpression of TGFβRII seem to inhibit the cell death induced by mutant AR255.  
These results suggest that the alteration induced by mutant androgen receptor lead to cytotoxic 
effects on neuronal cells associated with polyglutamine-mediated cellular damage10. 
Smads protein are retrogradely transported in axons by dynein-dynactin complex, usually altered by 
pathogenic AR. This alteration may enhance TGFβ signal disruption in SBMA. Moreover, the muscle-
specific expression of IGF-1 ameliorates motor neuron degeneration in a mouse model of SBMA. This 
result also supports the idea that TGFβ  and Smad signaling plays a protective role in the pathogenesis 
of motor neuron damage in SBMA, given the cross-talk between the IGF-1 and TGFβ pathways41. 
TGFβ in amyotrophic lateral sclerosis  
In ALS patients, TGFβ isoforms and their receptors are highly expressed in motor neurons, and it is 
observed in animal model that injection of TGFβ can reduce the motor neuron induced by axotomy. 
This evidence suggest that TGFβ may regulate motor neuron survival256. Moreover, sever analysis have 
detected high levels of TGFβ in plasma and serum of ALS patient, nevertheless the mechanisms that 
induce this increase are unclear257. Also the markers of TGFβ pathway, such as Smad2/3 and Smad 4, 
are increased in the spinal cord of ALS patient, analyzed post mortem258. All this evidence suggests 
that TGFβ may play and important role in disease pathogenesis but is not still clear if is causative or 
protective in motor neuron degeneration.    Some study seem to suggest a detrimental role of Smads 
signal induced by TGFβ in ALS259.  Indeed, active form of SMAD2 and 3 are find in Round hyaline 
inclusions (RHIs) in sALS motor neurons. Moreover, Smads protein colocalized with TDP-43, suggesting 
a sort of interference TGFβ-Smad2/3 signaling in the motor neurons of ALS cases 260. On the other 
hand, neither Bunina bodies in sporadic ALS nor Lewy body like hyaline inclusions in familial ALS cases 
with an SOD1 mutation show immunoreactivity for pSmad2/3.  TGFβ was also shown to protect 
neurons from glutamate-mediated excitotoxicity, a putative molecular mechanism underlying the 
pathogenesis of a variety of neurodegenerative disorders including motor neuron diseases.  
Based on this hypothesis, the possible neuroprotection induced by TGFβ was tested as a trial therapies 
for ALS. For instance, in mice characterized by the expression of mutant SOD1 protein, intraperitoneal  
injection of TGF β2 lead to an increase of mice motor activity261. A deep analysis shows also an increase 
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of motor neuron nuclei size and axons. These evidences suggest that TGFβ, through Smads signaling, 
may lead to a restoration of neuro muscular activity, and increase the motor neuron survival. 
However, neither the lifespan nor the numbers of motor neurons in the mutant SOD1 mice are 
improved by TGFβ2 administration. This study seems to indicate that systemic treatment with TGFβ 
may protect motor neurons from toxic protein insults in the short term, although the long-term effects 
of TGFβ on motor neuron degeneration has yet to be determined 262.  
 
 
 Chapter 2 - Aim 
63 
 
 
 
 
 
 
 
Aim 
  
 Chapter 2 - Aim 
64 
 
Aim 
Despite the apparent selectivity for motor neurons, multiple lines of evidence indicate that 
nonneuronal cell types contribute to pathogenesis and disease progression in SOD1-mediated 
neurodegeneration. Mutant SOD1 expression in motor neurons directs the onset and development of 
early disease but does not influence its progression 198. In contrast, mutant SOD1 expression in 
microglia or astrocytes accelerates disease progression without affecting its onset. Expression of a 
dismutase-active mutant SOD1 specifically in Schwann cells was found to slow disease progression, 
but the role of a dismutase-inactive mutant in these cells has not been tested 198. In the mutSOD1 
mouse model, the reduction of mutant protein in skeletal muscles has no effect on disease progression 
263, but the selective expression of mutSOD1 in skeletal muscle results in progressive muscle atrophy, 
although some reports suggest that muscle might be a direct target of mutant SOD1 toxicity. Lastly, 
the vasculature is damaged very early in disease, leading to loss of tight junctions between endothelial 
cells and microhemorrhages, but whether any of this is from mutant SOD1 within pericytes, the 
terminal astrocyte, or coming from cells outside the vasculature is not established 264. 
Thus, toxicity to motor neurons might also derive from their target muscular cells. Furthermore, 
muscle dysfunction and neuromuscular junction degeneration occur long before disease onset and 
motoneuronal death. Indeed, there are evidence of several alterations in gene expression and 
regenerative potential of skeletal muscles because of the expression of mutSOD1 in muscle 265,266. 
Among the genes identified as dysregulated in ALS muscle there is TGFβ 1.  
There is increasing evidence that TGFβ 1 promotes neuronal survival, maintains neuronal function, 
and protects neurons from various types of insults such as glutamate and amyloid β. Several studies 
suggest that the disruption of TGFβ 1 signaling is likely to be associated with the pathogenesis of motor 
neuron diseases. Given that the genes regulated by TGFβ 1 are implicated in a variety of molecular 
events including the cell cycle, it is of importance to elucidate the precise molecular mechanisms by 
which impaired TGFβ 1 Smad pathway induces neuronal dysfunction and cell death 267. The far-
reaching biological effects of TGFβ 1, however, may also include the induction of neuroinflammation 
and the suppression of muscle regeneration. These insights suggest the necessity for the successful 
manipulation of the neuroprotective and neurotoxic properties of TGFβ 1 for the development of 
therapies for motor neuron diseases. 
Unfortunately, there are no information available on TGF β 1 and its signaling pathway in ALS muscle. 
TGF β 1 functions are mediated by type I and type II transmembrane receptors forming a 
serine/threonine kinase complex. TGF β 1 binds to a homodimer of type II receptor which recruits and 
phosphorylates the type I receptor, which then phosphorylates Smad 2 and 3 (the receptor-regulated 
Smad proteins). These proteins after binding to the common Smad 4 translocate into the nucleus and 
act as transcription factors for target genes 268. It is reported that in ALS patient concentration of TGF 
β 1 in the serum is increased, and that it is signiﬁcantly higher in the cerebrospinal ﬂuid of the patients 
with a long duration of illness, suggesting a neuroprotective activity of this growth factor against toxic 
agents, such as free radicals, or glutamate excitotoxicity 269. Furthermore, in SOD1 mice the treatment 
with TGF β 2 produces an acute improvement in the motor performance, even if without preventing 
motor neurons loss. TGF β 1 is known to be implicated in different neurodegenerative diseases, like 
for example Alzheimer disease 270, and SBMA 255, both reporting an altered subcellular location of 
phosphorylated Smads (pSmads). An aberrant nucleocytoplasmic transport with an accumulation of 
cytoplasmic pSmad2/3 immunoreactivity has also been reported in ALS 259. A dysregulation of TGF β 
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type II receptor (TGF β -RII) levels is present in G93A spinal cords with a TGF β-RII immunoreactivity 
more intense predominantly in motor neurons of the ventral horns of G93A lumbar spinal cords 271.  
In this study, we decided to analyze the gene expression of TGF β 1 and of the related signaling 
molecules (TGF β -RII, Smad 2,3, and 4) both in the spinal cord and in the muscle of mutant human 
SOD1-G93A mice. We performed the analyses at pre-symptomatic and symptomatic stage, taking also 
in consideration mouse gender. Furthermore, we evaluated the expression of TGF β 1 also in a cohort 
of ALS patient. The results demonstrate that the expression of this growth factor is increased in tissues 
affected by ALS, both in mice and humans. The adverse effects of a TGF β 1 pathway dysregulation 
can reflect both on motor neurons (lack of neuroprotection) and muscle (fibrosis, deficient 
regeneration, cytoskeletal structure impairment). 
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Results 
TGFβ 1 gene expression  
We previously showed that in skeletal muscle of presymptomatic male G93A-SOD1 mice TGFβ1 
expression is upregulated compared to control male mice 266.  In addition, we found that the 
administration of nandrolone, an androgenic -   anabolic steroid, can enhances TGFβ 1 expression in 
these mice 266. For these reasons, we now evaluated whether gender influences TGFβ1 expression in 
the same ALS model. The study has been performed on 8 (presymptomatic, PS) and 16 (symptomatic, 
S) week-old G93A-SOD1 mice, compared to age-matched non-transgenic (NTg) mice, and to Tg mice 
expressing the human wt SOD1 (wt-SOD1). Each set of animals was divided into male and female 
groups, and the analyses performed on total RNA extracted from spinal cords and quadriceps muscles. 
In samples derived from spinal cord at the PS stage, TGFβ1 mRNA levels were reduced in G93A-SOD1 
mice in both sexes, when compared to age-matched control animals (Figure 20A). The decreased 
TGFβ1 mRNA expression was reverted at the S stage; in fact, TGFβ1 mRNA levels were found to be 
increased of about 50% when compared to the levels detected at PS stage of G93A-SOD1 mice in both 
sexes (Figure 20A). TGFβ1 gene expression in NTg and in wt-SOD1 mice remained unchanged in all 
examined conditions.  
On the other hand, in samples derived from the quadriceps muscles at the S stage, TGFβ1 mRNA levels 
were found to be greatly increased in G93A-SOD1 mice compared to the same animal at PS stage and 
to age-matched control mice in both sexes (Figure 20B). At the PS stage TGFβ1 mRNA levels were 
significantly upregulated only in male G93A-SOD1 animals (Figure 20B). Combined with our previous 
data, this observation corroborates the idea that at the muscular level male androgens exert a 
detrimental role in ALS, since they exacerbate some of the alterations induced by G93A-SOD1 266.  
 
 
Figure 20 - Tgfβ1 expression levels in G93A-SOD1 mice - RT-qPCR analyses of Tgfβ1 mRNA performed on total RNA 
extracted from spinal cord (A) or quadriceps muscles (B) of female and male mice NTg, Tg expressing either the wild type 
human SOD1 transgene (wt-SOD1) or the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 and 16 weeks of age. Data 
have been normalized to Rplp0 mRNA, expressed relative to the levels determined in female NTg mice at 8 weeks of age, 
which are taken as internal reference, and expressed as fold changes. Each bar represents the mean  s.e.m. of four 
independent replicates. *p<0.05; **p<0.01; ***p<0.001. Statistical analysis has been performed through two-way ANOVA 
for group comparisons followed by Bonferroni post-hoc test. 
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Since data from wt-SOD1 mice did not differ from those obtained from NTg animals, we decided to 
use the latter model as control for subsequent analyses. 
Next, we analyzed TGFβ1 protein expression (Figure 21). Western blot (WB) analysis of spinal cord 
lysates showed that, at S stage, TGFβ1 levels were increased when compared to PS stage both in male 
and female mice, even if this difference was not statistically significant (Figure 21A). In muscle at PS 
stage TGFβ1 levels were increased specifically in male G93A-SOD1 mice as compared to NTg mice. At 
the S stage, TGFβ 1 levels were increased in female and male G93A-SOD1 mice, as compared to NTg 
mice (Figure 21B).  
 
  
A B 
Figure 21 - Tgfβ1 protein levels in G93A-SOD1 mice - Representative immunoblot and densitometric analysis of Tgfβ1 and 
GAPDH proteins extracted from spinal cords (A n=3) and quadriceps muscles (B n=4) of female and male mice NTg, Tg 
expressing either the wild type human SOD1 transgene (wt-SOD1) or the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 
and 16 weeks of age. GAPDH was used to normalize protein loading. *p<0.05, **p<0.01, ***p<0.001. Statistical analysis has 
been performed through two-way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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We next wanted to investigate whether these differences in TGFβ1 expression observed in G93A-
SOD1 mice were also present in muscle biopsies derived from a cohort of ALS patients. Demographical 
and clinical data of ALS patients have been reported in Table 1. The results overlapped in muscle 
derived from rodent and human. In fact, as reported in Figure 22 the expression of TGFβ1 mRNA was 
increased in sALS patients (disease effect p=0.0003), and a statistically significant gender effect 
(p=0.0196) was observed, with TGFβ1 mRNA levels increased by 73% in female (from 1±0.15 to 
1.73±0.43), and by 106% in male (from 0.63±0.06 to 1.30±0.16). Thus, modifications of TGFβ1 levels 
could be related to the male higher risk of developing ALS as well as it may represent a marker of some 
specific alterations occurring in muscle of ALS patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72 - Tgfβ1 levels in patients -RT-qPCR analyses of Tgfβ1 mRNA levels from muscles biopsies of male and female human 
controls and ALS patients. Disease effect p=0.0003; gender effect p=0.0196; *p<0.05; **p<0.01. Statistical analysis has been 
performed through two-way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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Table 1 - Tgfβ1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients. 
Abbreviations: y=years; m=months; VL=vastus lateralis; CAN=chronic neurogenic atrophy; NA=not available 
 
 
 
 
 
  
Patient Sex Age at biopsy (y) Time onset (m) Site of biopsy Clinical diagnosis 
1 F 76 24 VL CNA 
2 F 68 6 VL CNA 
3 F 73 NA VL CNA 
4 F 67 12 VL Early neurogenic atrophy 
5 F 71 12 VL CNA 
6 F 67 10 VL CNA 
7 F 47 36 VL CNA 
8 F 50 24 VL CNA 
9 F 56 2 Biceps brachii CNA 
10 F 58 8 VL CNA 
11 M 77 4 VL CNA 
12 M 32 12 VL CNA 
13 M 61 36 VL Early neurogenic atrophy 
14 M 61 12 VL CNA 
15 M 58 36 VL CNA 
16 M 42 12 VL CNA 
17 M 61 8 VL CNA 
18 M 53 24 VL CNA 
19 M 69 6 VL CNA 
20 M 56 2 VL CNA 
21 M 83 24 VL CNA 
22 M 62 4 Triceps CNA 
23 M 79 5 Biceps brachii CNA 
Control Sex Age at biopsy (y)  Site of biopsy Clinical diagnosis/source 
1 F 47  VL Mild non-specific myopathy 
2 F 73  VL Mild non-specific myopathy 
3 F 40  Gluteus Orthopedic surgery 
4 F 70  NA Orthopedic surgery 
5 F 64  VL Within normal limits 
6 F 49  Biceps brachii Within normal limits 
7 F 63  VL Within normal limits 
8 F 41  Biceps brachii Mild non-specific myopathy 
9 F 65  VL Mild non-specific myopathy 
10 M 45  VL Mild non-specific myopathy 
11 M 45  VL Mild non-specific myopathy 
12 M 50  VL Mild non-specific myopathy 
13 M 70  VL Prevalence of type I fiber 
14 M 19  VL Within normal limits 
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TGFβ1 signaling 
Not only TGFβ1 levels, but also its signaling pathway is dysregulated in different neurodegenerative 
diseases 271. Thus, we evaluated possible variations of the mRNA levels of TGFβRII, the membrane 
receptor engaged by TGFβ1, both in the spinal cord and in the quadriceps muscle of PS, and S G93A-
SOD1 and age-matched NTg mice. In spinal cord samples, TGFβRII expression was found increased in 
G93A-SOD1 at S stage in both sexes (Figure 23A). On the contrary, in quadriceps muscles, TGFβRII 
expression remained unchanged in all samples considered (Figure 23B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 23 - TgfβRII levels - RT-qPCR analyses of TgfβRII mRNA performed on total RNA extracted from spinal cord (A) and 
quadriceps muscle (B) of female and male mice [NTg (non-transgenic), and Tg mice expressing the G93A mutant form of 
human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) and 16 (symptomatic stage) weeks of age. Data have been 
normalized to Rplp0 mRNA, expressed relative to the levels determined in female NTg mice at 8 weeks of age, which are 
taken as internal reference and expressed as fold changes. Each bar represents the mean  s.e.m. of four independent 
replicates. **p<0.01, ***p<0.001. Statistical analysis has been performed through two-way ANOVA for group comparisons 
followed by Bonferroni post-hoc test. 
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Then, we evaluated the expression of Smads, which are the canonical intracellular mediators of TGFβ1 
signaling pathway. In spinal cord samples, we found that mRNA expression of Smad2 and 3 are 
differently regulated; Smad2 expression diminished during disease progression (Figure 24A), while 
Smad3 expression remained unchanged (Figure 24B). In quadriceps muscles, the Smad2 mRNA levels 
diminished during disease progression (Figure 24C), showing a pattern like that found in the spinal 
cord. On the contrary, Smad3 mRNA levels were up-regulated at S compared to PS stage in both sexes 
(Figure 24D).  
 
 
 
 
 
 
 
 
 
 
 
Figure 84 – SMADs expression in ALS tissues are dysregulated - RT-qPCR analyses of the mRNA levels of Smads2 and 3 
performed on total RNA extracted from spinal cord (A,B) or quadriceps muscles (C,D) of female and male mice [NTg (non-
transgenic), Tg expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 
(symptomatic stage) weeks of age. Data have been normalized to Rplp0 mRNA, expressed relative to the levels determined 
in female NTg mice at 8 weeks of age, which are taken as internal reference, and expressed as fold changes. Each bar 
represents the mean  s.e.m. of four independent replicates (*p<0.05, **p<0.01). Statistical analysis has been performed 
through two-way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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By WB assay of quadriceps muscles, we found that Smad2 and 3 protein levels are both upregulated 
at S stage in both sexes (Figure 25). At the PS stage, Smad2 and 3 levels were not changed in G93A-
SOD1 mice respect to NTg mice, even if their levels tend to be higher in male than in female mice, in 
line with the variations found for TGFβ 1 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 95 – SMAD’s protein levels are dysregulated -Representative immunoblot and densitometric analyses of SMAD2 and 
3 extracted from spinal cords (n=3) or quadriceps muscles (n=4) of female and male NTg, and G93A-SOD1mice, at 8 or 16 
weeks of age. GAPDH was used to normalize protein loading. Images have been cropped from different parts of the same 
gel, and full-length blots are included in the Supplementary Figure 1.  *p<0.05; **p<0.01. Statistical analysis has been 
performed through two-way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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We also evaluated variations of Smad 4, the common Smad shared among different members of the 
TGFβ superfamily (TGFβ s, BMPs, activins, etc.), and found that in spinal cord of G93A-SOD1 mice Smad 
4 mRNA levels are gender related, being reduced during disease progression in female, but not in male 
samples (Figure 26A). In quadriceps, Smad 4 mRNA levels were reduced at the S stage compared to PS 
stage in G93A-SOD1 mice in both sexes (Figure 26B). 
These data indicate that changes in Smad levels, both in muscle and spinal cord, reflect TGFβ 1 
changes, and that the gene expression of the two receptors regulated Smads is differently controlled. 
Furthermore, also the tissue specific modulation of the TGFβ RII expression could mediate different 
roles of TGFβ 1 in muscle and spinal cord. 
 
 
 
   
Figure 106 – SMAD4 dysregulation in G93A mice -RT-qPCR analyses of Smad4 mRNA performed on total RNA extracted from 
spinal cord (A) or quadriceps muscles (B) of female and male mice [NTg (non-transgenic), and Tg expressing the G93A mutant 
form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have been 
normalized to Rplp0 mRNA, expressed relative to the levels determined in female NTg mice at 8 weeks of age, which are taken as 
internal reference, and expressed as fold changes. Each bar represents the mean  s.e.m. of four independent replicates. * 
p<0.05, **p<0.01, ***p<0.001. Statistical analysis has been performed through two-way ANOVA for group comparisons 
followed by Bonferroni post-hoc test. 
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TGFβ 1 in ALS muscle 
To understand the impact of the upregulation of TGFβ 1 in ALS muscle, we analyzed different pathways 
known to mediate the effect of TGFβ1 on muscle development, and functions. It is known that TGFβ1 
could suppress muscle differentiation by inhibiting the expression of muscle specific genes 266, and 
hamper muscle regeneration in muscular diseases, likely by inhibiting satellite cell proliferation and 
myofiber fusion. The normal functions of satellite cells during myogenesis are mainly regulated by the 
transcription factor Pax7, which in turn is known to be modulated by TGFβ. Thus, we analyzed whether 
Pax7 expression is altered in G93A-SOD1 mouse muscles. The results (Figure 27A) show that Pax7 
mRNA levels are reduced in G93A-SOD1 mice at S stage compared to PS stage and to NTg mice and no 
gender effect was present.  To evaluate whether this effect could be generally ascribed to myofiber 
denervation, we measured Pax7 expression in two other conditions characterized by motor neuron 
loss: i) muscles derived from acutely axotomized NTg mice; ii) muscles from a mouse model of SBMA 
(spinal bulbar muscular atrophy, or Kennedy’s disease), which represent another type of motor 
neuron disease sharing some features with ALS. In our analysis we found that denervation due to 
axotomy (7 days) did not lead to modification of Pax7 expression, while an increased Pax7 expression 
was detected in muscle of SBMA mice at S stage (24 weeks) compared to age-matched control NTg 
mice (Figure 27B, 27C). Therefore, the reduction of Pax7 in the ALS muscle could be due to a specific 
action of G93A-SOD1 and could lead to an impairment of muscle regeneration. 
 
 
 
Figure 117 – Pax7 expression in denervated muscle - RT-qPCR analyses of the Pax7 mRNA levels performed on total RNA 
extracted from: (A) quadriceps muscles of female and male mice [NTg (non-transgenic), and transgenic expressing the G93A 
mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have 
been normalized to of Rplp0 mRNA, expressed relative to the levels determined in female NTg mice at 8 weeks of age, which 
are taken as internal reference, and expressed as fold changes. Each bar represents the mean  s.e.m. of four independent 
replicates. ***p<0.001.  (B) gastrocnemius muscles of left axotomized non-transgenic mice (Axo). Right gastrocnemius 
muscles of the same animals were used as controls (Ctrl). Data have been normalized to the amount of Rplp0 mRNA, 
expressed relative to the levels determined in control muscles, which are taken as internal reference, and expressed as fold 
changes. (C) quadriceps muscles of male non-transgenic (WT) mice, and of Knock In AR113Q (SBMA) mice at 24 weeks of age 
(corresponding to symptomatic stage). Animals were age-matched. Data have been normalized to the amount of Rplp0 
mRNA, expressed relative to the levels determined in WT mice taken as internal reference, and expressed as fold changes. 
**p<0.01, ***p<0.001.  Statistical analysis has been performed through two-way ANOVA for group comparisons followed by 
Bonferroni post-hoc test. 
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Since in different muscle disorders, TGFβ1 promotes an aberrant differentiation of myogenic cells to 
myofibroblasts inducing fibrosis, and muscular fibrosis is a major pathological feature of ALS, we 
analyzed in G93A-SOD1 mice the mRNA expression of two extracellular matrix protein, widely 
considered as hallmark of fibrosis: collagen 1alpha1 (Col1α1), and fibronectin (FN). Surprisingly, we 
found that in muscle tissues of both G93A-SOD1 and control mice the expression of Col1α1 is 
massively reduced at 16 weeks of age (corresponding to S stage in G93A-SOD1) as compared to mice 
at 8 weeks of age (corresponding to PS stage in G93A-SOD1) (Figure 28A). The FN expression was also 
greatly reduced in muscle tissue from G93A-SOD1 at S stage as compared to PS stage and to age 
matched controls, while no differences were present in control NTg mice at the two ages considered 
(Figure 28B). To determine whether the effect on Col1α1 and FN gene expression is due to G93A-SOD1 
or to denervation, we measured their expression in axotomized mouse muscle. Figure 28C and 28D 
indicates that denervation due to acute axotomy caused a dramatic increase in Col1α1 and FN 
expression, strongly suggesting that the reduction in the expression of these two genes in muscle of 
G93A-SOD1 is not due to motor neuron loss and muscle denervation, but probably is due to the 
presence of the G93A-SOD1 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 128 – Change in Collagen 1α1 and Fibronectin -(A,B) RT-qPCR analyses of Collagen (Col) 1α1 and Fibronectin (Fn) 
mRNA levels performed on total RNA extracted from quadriceps muscles of female and male mice [NTg (non-transgenic), 
and  transgenic expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 
(symptomatic stage) weeks of age. Data have been normalized to the amount of Rplp0 mRNA, expressed relative to the 
levels determined in female NTg mice at 8 weeks of age, which are taken as internal reference, and expressed as fold 
changes. Each bar represents the mean  s.e.m. of four independent replicates. *p<0.05, **p<0.01, ***p<0.001.  (C, D) RT-
qPCR analyses of Col1α1 and Fn mRNA levels performed on total RNA extracted from gastrocnemius muscles of left 
axotomized NTg mice (Axo). Right gastrocnemius muscles of the same animals were used as controls (Ctrl). Data have been 
normalized to the amount of Rplp0 mRNA, expressed relative to the levels determined in control muscles, which are taken 
as internal reference, and expressed as fold changes. **p<0.01, ***p<0.001. Statistical analysis has been performed 
through two-way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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To validate this hypothesis, we analysed the expression of Col1α1 and FN in an in vitro model of ALS 
muscle, based on C2C12 cells transiently transfected with G93A-SOD1 266. Accordingly, with our 
previous results, we found that TGFβ1 expression is increased in C2C12 expressing G93A-SOD1 as 
compared to control C2C12 cells (pcDNA3) (Figure 29A); indeed, in the same experimental conditions 
the presence of G93A-SOD1 protein reduced Col1α1 and FN mRNA levels (Figure 29B, 29C). No effect 
was detected in cells transfected with the wt-SOD1 (Figure 29).  
 
 
 
A B C 
Figure 29 - Tgfβ1, Col1α1 and Fn dysregulation in C2C12 - RT-qPCR analyses of Tgfβ1, Col1α1 and Fn mRNAs, performed on 
total RNA extracted from C2C12 cells transfected with wild type human SOD1 (wt-SOD1) or G93A mutant form of human 
SOD1 (G93A-SOD1). Data have been normalized to the amount of Rplp0 mRNA, expressed relative to the levels determined in 
control cells (mock transfected, pcDNA3), which are taken as internal reference, and expressed as fold changes. Each bar 
represents the mean ± s.e.m. of four independent replicates. *p<0.05. Statistical analysis has been performed through two-
way ANOVA for group comparisons followed by Bonferroni post-hoc test. 
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Discussion 
In the last few years it has become clear that ALS is not a cell autonomous disease of motor neuron, 
but other cell types are involved and modulate ALS onset and progression. Based on other and our 
previous works, muscle cells could also be a primary target of G93A-SOD1 mediated toxicity 266. Our 
data confirm and expand those previously obtained on the expression of TGFβ 1 in ALS affected 
tissues. Since gender is a risk factor for developing ALS, here we differentially analyzed and compared 
female and male tissues. The results indicate that TGFβ 1 is highly expressed in muscle at the S stage 
both in female and male mice, and that the increase of TGFβ 1 mRNA levels takes place much earlier 
in male than in female (at the PS stage). Since TGFβ 1 is an androgen responsive gene, it is possible to 
hypothesize that the increased risk of ALS in males is linked to the higher serum levels of male sex 
steroids. This hypothesis is corroborated by the fact that TGFβ 1 gene expression resulted to be 
increased in muscle biopsies of ALS patients and that, also in this case, the increase is greater in male 
than in female. Other Authors have studied the involvement of TGFβ 1 in ALS disorder. High TGFβ 1 
plasma levels have been detected in ALS patients, with a significant positive correlation with disease 
duration 257, while other results reported that expression levels of endogenous TGFβ 1 mRNA at the 
end stage negatively correlates with the survival time of G93A-SOD1 mice. All these results indicate 
that TGFβ 1 might be a potential biomarker of ALS progression in males and females, might predict 
disease onset in fALS males. 
With regards the specific role of TGFβ 1 in ALS, it must be recalled that in the nervous system TGFβ 1 
is neuroprotective 272; indeed, a reduced neuronal TGFβ signaling is implicated in age-dependent 
neurodegeneration 273. Conversely, in muscle an excessive presence of TGFβ 1 is considered a harmful 
factor. Gene expression analysis in the spinal cord of mice expressing G93A-SOD1 showed decreased 
TGFβ 1 levels at the PS stage, possibly indicating a lack of neuroprotective effects in the early stages 
of disease leading to the death of motor neurons at later stages. In ALS mouse spinal cord, TGFβ 1 
mRNA levels have a huge increase with disease progression that can be explained with the 
development of reactive astrogliosis 271. Indeed, astrocyte-derived TGFβ 1 accelerates ALS 
progression, while the same parameter is counteracted by the administration of a TGFβ signaling 
inhibitor 36. Furthermore, the effects of TGFβ 1 are also mediated by the inhibition of microglial 
activation with the consequent reduction of neuroprotective properties of microglial cells 10. 
The first step of TGFβ 1 signaling pathway is the binding to the type II receptor. Our study indicated 
that the TGF β-RII mRNA levels are increased in the spinal cord at the S stage but remained unchanged 
in the muscle. These results agree with previous studies showing a high TGFβ-RII immunoreactivity in 
spinal cord motor neurons of mice expressing G93A-SOD1 which correlates with reactive astrogliosis 
and disease progression 271. The higher TGFβ-RII expression might also correlate with dysregulation of 
the intracellular pathway mediating TGFβ effects. In fact, we found a diminished Smad2 expression in 
the spinal cord of ALS mice. The regulation of Smad2 and 3 in the muscle seems to be more complex. 
In fact, while Smad2 and 3 proteins are both increased at the S stage, data on their gene expression 
are divergent being Smad2 mRNA reduced, and Smad3 mRNA increased. Although Smad2 and 3 are 
usually grouped together as receptor-activated Smads, Smad2 is unable to bind DNA directly as 
Smad3. Furthermore, in some systems Smad2 and Smad3 are antagonists, suggesting that their 
relative levels determine different biological response (Labbe, 1998). Additionally, it has been 
reported a decrease of Smad2, accompanied by an activation of Smad3, in culture of hepatic cells 
becoming fibrogenic. Thus, Smad2 and Smad3 could mediate different cellular responses, and this is 
also supported by data showing that Smad2 knockout is lethal at the embryonic stage, whereas Smad3 
 Chapter 2 - Discussion 
80 
 
knockout mice survive to adulthood. Additionally, to be imported into the nucleus the phosphorylated 
Smad3 associates with importin-beta in the cytoplasm, whereas the phosphorylated Smad2 is 
autonomously imported into the nucleus. Seems that a disturbed Smad nuclear translocation may 
impair the neuroprotective TGFβ signaling, leading to neurodegeneration. The common Smad 4 is the 
protein that shuttles receptor regulated Smads into the nucleus, even if Smad4 independent effects 
of TGFβ have been described. We found a decreased Smad 4 expression both in spinal cord and 
muscle, suggesting a further site of dysregulation of TGFβ intracellular signaling. 
TGFβ profoundly influences the differentiation of myoblasts inhibiting the induction of muscle-specific 
gene expression and myotube formation 246; this suggests that it targets one or more master 
regulators of myogenesis, such as Pax7. Indeed, an impaired regenerative capacity concomitant with 
a progressive loss in satellite cell number has been reported in Pax7-null mice 214. Notably, we found 
that Pax7 expression is decreased in muscle of ALS mice at the S stage, and this may suggest that the 
myogenic potential and the ability for tissue repair of ALS muscle is impaired. This hypothesis agrees 
with a previous work on G93A-SOD1 mice and has been recently confirmed in patient biopsies showing 
a reduction in mRNA levels of satellite cells and early myogenic markers. The effect on Pax7 gene is a 
specific feature of ALS disease, since denervation induced by axotomy does not alter Pax7 mRNA 
levels. In agreement, Pax7 gene expression is increased in muscle of the mouse model of SBMA, 
another disease characterized by progressive death of motor neuron and denervation. 
TGF β 1 can promote an aberrant differentiation of myogenic cells to myofibroblasts inducing fibrosis 
118, which is a pathological feature of ALS. Col1α1 gene expression is age dependent in NTg mice, in 
line with the normal age-related rearrangement of skeletal muscle fibers and of the connective tissue 
network. Surprisingly, in ALS mice we found that Col1α1, and FN mRNA levels were much lower at S 
than at PS stage. This effect is not due to denervation, since in axotomized muscle the expression of 
these two extracellular matrix proteins is highly increased. On the other hand, Col1α1, and FN mRNA 
reduction could be due to the decline in the ability to move of mice during disease progression, since 
poor mobility downregulates total muscular collagen synthesis 274. Furthermore, in the ALS muscle 
cellular model the expression of the G93A-SOD1 lead to decreased levels of Col1α1, and FN mRNA, 
indicating that mutant SOD1 could be directly responsible of the Col1α1, and FN gene expression 
modulation. It is possible that the decrease in collagen expression is an attempt to prevent collagen 
accumulation that leads to fibrosis; a similar mechanism has been proposed in hepatic cells. It has 
been demonstrated that TGFβ is able to promote Col1α1 transcription through specific responsive 
sequence, therefore it remains to understand why the levels of Col1α1 mRNA, and of FN, are reduced 
in the presence of high levels of TGFβ 1. A possible explanation comes from a work demonstrating 
that high doses of TGFβ potently suppress Col1α1 transcription via the transcription factor CUX1 275. 
In conclusion, data in this second chapter indicate that TGFβ 1 and its signaling pathway are altered in 
ALS affected tissues even at PS stage of disease. In spinal cord, the reduction of TGFβ 1 expression 
could reflect a lack of its neuroprotective effect. In muscle, the higher levels of TGFβ 1 could contribute 
to muscular atrophy since this correlates with an altered differentiation of satellite cells, and changes 
in extracellular matrix production. Androgen sensitivity of TGFβ 1 and its higher levels in males could 
also be a possible explanation of their higher risk of developing ALS. All together these data increase 
the possibilities of new and complementary therapies to treat the disease or, at least, to delay muscle 
wasting. Furthermore, TGF β 1 could also be proposed as a biomarker of ALS disease. 
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Materials and methods 
ANIMAL MODELS 
Mice were maintained according to the institutional guidelines, that follow national (D.L. 26/2014) 
and European laws and policies (2010/63/UE). All the experimental procedures were approved by the 
Italian Ministry of Health. All the animals were kept under controlled temperature and humidity 
conditions, with dark/light cycles of 12 h. Food and water were supplied ad libitum. 
ALS model 
BL6JLTg(SOD1)2Gur/J (Stock number 002297, The Jackson Laboratory) male mice or BL6JL-Tg (SOD1-
G93A)2Gur/J (Stock number 002726, The Jackson Laboratory) male mice were crossed with wild type 
female mice purchased (Stock number 100012, Charles River) or obtained in house by crossing 
C57Bl/6J female and SJL male mice. All the experiments were performed in mice coming from the F1 
generation of the cross described above. Non-transgenic (NTg) littermates were used as controls. The 
genotyping of the litters was conducted by PCR on tail biopsy DNA as previously described182,266. To 
evaluate disease stages, starting from the 8th week of age and twice a week, mice were tested for the 
deficits by rotarod, and hanging wire by the same operator as previously described (Aggarwal et al., 
2014). Body weight loss was also monitored. Disease onset was set as the time at which the mouse 
permanently starts to lose body weight. Four mice per group were anesthetized with isoflurane and 
sacrificed at 8 or 16 weeks of age, corresponding to presymptomatic (PS) or symptomatic (S) stage of 
disease. Spinal cord and quadriceps muscles were rapidly collected after the sacrifice, snap frozen on 
dry ice, and conserved at -80°C until extraction. 
SBMA model 
Generation and genotyping of mice containing the exon 1 of the human androgen receptor gene with 
113 CAG repeats (AR113Q mice) has been previously described 75,184. Mice genetic background was 
C57Bl/6J. Females carrying one copy of AR113Q in the X chromosome were crossed with C57Bl/6J 
mice to maintain the colony. Genotypes were verified by PCR on tail DNA. Symptomatic mice of 24 
weeks of age were anesthetized with isoflurane and sacrificed; quadriceps muscles collected, snap 
frozen, and maintained at –80°C. 
Denervation model 
Three-months-old NTg male mice were anaesthetized with ketamine and xylazine. An incision was 
made through the skin and the upper region of the left gluteal muscle to expose the sciatic nerve, 
which was then cut 1–2 mm distal to the sciatic notch. The proximal portion of the nerve was sutured 
to prevent errant re-innervation of the gastrocnemius muscle. Right sciatic nerve was exposed and 
utilized as sham internal control in each animal. Mice were sacrificed 7 days later, and gastrocnemius 
muscles collected, snap frozen and conserved at -80°C. 
Human samples 
All evaluations involving anonymized controls and patients and experiments involving muscle tissue 
samples were performed in accordance with relevant guidelines and regulations and were approved 
by the University of Padova Ethics Committee for Clinical Experimentation. Written informed consent 
to study procedures was obtained from each patient, or his legal guardians. Confidentiality was 
guaranteed by assigning a study code to each patient. Bioptic samples were conserved in a genetic 
biobank supported by Telethon, Italy, fully complying with highest quality standards, according to 
rigorous ethical principles complying with Italian laws and International Recommendations. All 
patients were clinically affected with the definite ALS diagnosis, according to the revised El Escorial 
criteria276 and were followed at Neuromuscular Clinic of the University of Padova. Supplementary 
table 1 reports demographic and clinical data of twenty-three ALS patients enrolled (ten females and 
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thirteen males). Control bioptic samples were obtained from healthy aged-matched subjects (nine 
females and five males), who had undergone hip arthroprosthesis. Muscle biopsies were obtained 
using an open biopsy procedure and 100–200 mg of muscle tissue was collected. All biopsies were 
immediately frozen in liquid nitrogen for histopathology and biochemical analyses and stored at −80°C 
until analyzed. Total RNA was isolated from frozen muscle biopsies using TRIzol Reagent (Sigma-
Aldrich), according to the manufacturer’s instructions. 
Cell cultures 
The myoblast C2C12 cell line was originally obtained from the American Type Culture Collection 
(Rockville, MD, USA). The cell line was routinely maintained in high glucose (4500 mg/L) Dulbecco's 
modified Eagle's medium (Biochrom KG, Berlin, Germany) supplemented with 4 mM glutamine, 1 mM 
sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (Thermo 
Fisher Scientific, Monza, Italy) at 37°C with 5% CO2. The plasmids pcDNA3-wtSOD1, pcDNA3-
G93ASOD1266, were transiently transfected into C2C12 using Lipofectamine 2000TM (Thermo Fisher 
Scientific) following Manufacturers’ instructions. Briefly, 60,000 cells/ml were plated in 12-well dishes, 
and transfected with 1,6 µg of DNA, and 4 µL of Lipofectamine/well. Controls were mock transfected. 
Cells were harvested for RNA isolation at 48 h after transfection.  
 
WESTERNBLOTTING ASSAY 
Vivo  
Total proteins from muscles were extracted in 1% SDS using the standard TRI Reagent protocol, in 
accordance with the manufacturer’s protocol (Sigma-Aldrich). Protein concentration was determined 
with the bicinchoninic acid method (BCA assay, EuroClone, Pero, Milan, Italy). Western immunoblot 
analysis was performed on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis loading 15 
μg of total proteins. Samples were then electrotransferred to nitrocellulose membranes (Trans-blot, 
Bio-Rad Laboratories, Hercules, CA, USA) using a semi-dry transfer apparatus (Trans-Blot® Turbo™ 
Transfer System, Bio-Rad). Nitrocellulose membranes were treated with a blocking solution containing 
5% non-fat dry milk in TBS-T overnight and then incubated with the primary antibodies overnight at 
4 °C: 
 
rabbit polyclonal anti-phospho-Smad2 (Calbiochem, dilution 1:1000) 
rabbit polyclonal anti-phospho-Smad3 (Merck Millipore, diluition 1:1000) 
mouse monoclonal anti-TGFβ1 (R&D, diluition 1:1000) 
rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnology, dilution 1:1000). 
 
Immunoreactivity was detected using the following secondary peroxidase-conjugated antibodies:  
goat anti-rabbit (Santa Cruz Biotechnology diluition 1:5000) was used to identify anti-phospho-Smad2, 
anti-phospho-Smad3 and anti-GAPDH; goat anti-mouse (Santa Cruz Biotechnology diluition 1:5000) 
was used to identify the anti-TGFβ1 antibody.  
The immunoreactive regions were then visualized using the enhanced chemiluminescence detection 
kit reagents (ECL; GE Healthcare). A ChemiDoc XRS System (Bio-Rad) was used for the image 
acquisition. Optical intensity of samples assayed was detected and analyzed using the Image Lab 
software (Bio-Rad). 
 
Vitro 
For western blot assays, C2C12 cells were plated in 12-well multiwells at 65 000 cells/mL density. 
Transient transfections were performed transfecting 1 μg of pCDNA3, wt or G93A-SOD1 plasmids 
transfected 4 μL of Lipofectamine 2000.  
After 48 h from transfection, cells were harvested and centrifuged 5 min at 100 g at 4°C; the pellets 
of cells were resuspended in PBS (added of a protease inhibitors cocktail, Sigma Aldrich) and 
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homogenized using slight sonication. Total proteins were determined with the bicinchoninic acid 
method (BCA assay, Pierce, Rockford, IL, USA). Western immunoblot analysis was performed on 12% 
sodium dodecyl sulfatepolyacrylamide gel electrophoresis loading 15 μg of total proteins. Samples 
were then electrotransferred to nitrocellulose membranes (Trans-blot, Bio-Rad Laboratories, 
Hercules, CA, USA) using a semi-dry transfer apparatus (Trans-Blot® Turbo™ Transfer System, Bio-Rad).  
Nitrocellulose membranes were treated with a blocking solution containing 5% non-fat dry milk in 
TBS-T overnight and then incubated with the primary antibodies overnight at 4 °C: 
 
rabbit polyclonal anti-phospho-Smad2 (Calbiochem, dilution 1:1000) 
rabbit polyclonal anti-phospho-Smad3 (Merck Millipore, diluition 1:1000) 
mouse monoclonal anti-TGFβ1 (R&D, diluition 1:1000) 
rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnology, dilution 1:1000). 
 
Immunoreactivity was detected using the following secondary peroxidase-conjugated antibodies:  
goat anti-rabbit (Santa Cruz Biotechnology diluition 1:5000) was used to identify anti-phospho-Smad2, 
anti-phospho-Smad3 and anti-GAPDH; goat anti-mouse (Santa Cruz Biotechnology diluition 1:5000) 
was used to identify the anti-TGFβ1 antibody.  
The immunoreactive regions were then visualized using the enhanced chemiluminescence detection 
kit reagents (ECL; GE Healthcare). A ChemiDoc XRS System (Bio-Rad) was used for the image 
acquisition. Optical intensity of samples assayed was detected and analyzed using the Image Lab 
software (Bio-Rad). 
 
mRNA EXTRACTION  
Tissues (ALS) 
Total RNA from frozen spinal cords or muscles was extracted using the standard TRI Reagent protocol 
based on the method developed by Chomczynski and Sacchi (Chomczynskiand Sacchi, 1987).  
RNA was subsequently extracted in accordance to manufacturer’s protocol (Sigma-Aldrich). The 
precipitated RNA was dissolved in RNase-free water. Total RNA (1µg) was treated for 15min at room 
temperature with 1U of DNaseI (SigmaAldrich). Samples were reverse-transcribed using the 
HighCapacity cDNA Reverse Transcription Kit (Life Technologies Corporation, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. 
 
Tissues (SBMA) 
Total RNA from frozen spinal cords or muscles was extracted using the standard TRI Reagent protocol 
based on the method developed by Chomczynskiand Sacchi (Chomczynskiand Sacchi, 1987) and 
purified using Direct-zol RNA miniprep Plus kit (ZYMO RESEARCH) according to the manufacturer’s 
instructions.  
RNA was subsequently extracted following manufacturer’s protocol (Sigma-Aldrich). The precipitated 
RNA was dissolved in RNase-free water. Samples were reverse-transcribed using the HighCapacity 
cDNA Reverse Transcription Kit (Life Technologies Corporation, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. 
 
Cell cultures 
C2C12 were plated in 6-well multiwells at 65 000 cells/mL density. After 24 h, cells have been 
transfected with 2 μg of plasmids coding for pCDNA3, wt or G93A-SOD1 with addition of 8 μL of 
Lipofectamine 2000 for each sample. After 24 h, cells were harvested and centrifuged 5 min at 100 g 
at 4°C; the pellets were resuspended in 300 μl of TRI Reagent (Sigma-Aldrich) and RNA isolated 
according to manufacturer's instruction. RNA quantification was carried out by absorbance at 260 nm. 
Total RNA (1 μg) was treated with DNAse (Sigma-Aldrich), and reverse transcribed into cDNA using the 
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High-Capacity cDNA Archive Kit (Life Technologies Corporation) according to the manufacturer's 
protocol 
 
mRNA EXPRESSION ANALYSIS 
Primers for selected genes were designed using the program Primer 3 and purchased from Eurofins 
MWG Operon (Ebersberg, Germany) with the following sequence: 
 
mRplP0: 5′-GGT GCC ACA CTC CAT CA-3′ (forward), 5′-AGG CCT TGA CCT TTT CAG TAA GT-3′ (reverse) 
 
AchR: 5’-GTG CTG GGC TCT TTC ATC TC -3′ (forward), 5′ -TTC TGT GCG CGT TCT CAT AC -3′ (reverse) 
 
MyoD: 5′ -GGC TAC GAC ACC GCC TAC TA -3′ (forward), 5′ -GTG GAG ATG CGC TCC ACT AT -3′ (reverse) 
 
Myogenin: 5′ -GGG CAA TGC ACT GGA GTT -3′ (forward), 5′ -CAC GAT GGA CGT AAG GGA GT -3′ 
(reverse) 
 
mPax7: 5′-GTA TGG CCA AAC TGC TGT TGA T-3′ (forward), 5′-GGA GTG TTC CCC AAG CTT CA-3′ 
(reverse) 
 
PGC1-α: 5′ -GGA ATG CAC CGT AAA TCT GC -3′ (forward), 5′ -TTC TCA AGA GCA GCG AAA GC-3′ (reverse) 
 
BAG3: 5′ -ATG GAC CTG AGC GAT CTC A -3′ (forward), 5′ -CAC GGG GAT GGG GAT GTA -3′ (reverse) 
 
p62/ SQSTM-1: 5′ -AGG GAA CAC AGC AAG CT -3′ (forward), 5′ -GCC AAA GTG TCC ATG TTT CA -3′ 
(reverse) 
 
Beclin1: 5′ -TGA AAT CAA TGC CTG GG-3′ (for- ward), 5′ -CCA GAA CAG TAT AAC GGC AAC TCC -3′ 
(reverse) 
 
HSPB8: 5′ -ATA CGT GGA AGT TTC AGG CA -3′ (forward), 5′ -TCC TTT GAC CTA ACG CAA CC -3′ (reverse) 
 
mTGFβ1: 5′-GAA GGA CCT GGG TTG GAA GT-3′ (forward), 5′-CGG GTT GTG TTG GTT GTAGA-3′ (reverse) 
 
mTGFβRII: 5′-AGT CGT TCA AGC AGA CGG AT-3′ (forward), 5′-CCT TCA CTT CTC CCA CAG CAT T-3′ 
(reverse) 
 
mSmad 2: 5′-GTA AGA TCC CAC CAG GCT GTA A-3′ (forward), 5′- CTC CCC AGC CCT TCA CAA AA -3′ 
(reverse) 
 
mSmad 3: 5′-CGG TCA AGA GCT TGG TGA AGA A-3′ (forward), 5′-TCC AGT GAC CTG GGG ATG GTA A-
3′ (reverse) 
 
mSmad 4: 5′-CAA GTC AGC CGG CCA GTA TT-3′ (forward), 5′-CCA GGT AGT GCT GTT ATG-3′ (reverse) 
 
mCollagen 1α1: 5′-CGG CTC CTG CTC TTA G-3′ (forward), 5′-GGT TTC CAC GTC TCA CCA TT-3′ (reverse) 
 
mFibronectin: 5′-GAC CAC TCC CAA AAA TG-3′ (forward), 5′-TTG CAA ACC TTC AAT GGT CA-3′ (reverse) 
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hRplP0: 5′-GTG GGA GCA GACAAT GTG GG-3′ (forward), 5′-TGC GCA TCA TGG TGT TCT TG-3′ (reverse) 
 
hTGFβ1: 5′-GCA GGG ATA ACA CAC TGC AA-3′ (forward), 5′-GGT GGC CAT GAG AAG CAG-3′ (reverse) 
 
Real-time PCR was performed using the CFX 96 Real-Time System (Bio-Rad, Hercules, CA, USA) in a 10 
µl total volume, using the iTaq SYBR Green Supermix (Bio-Rad), and with 500 nm primers. PCR cycling 
conditions were as follows: 94°C for 10 min, 40 cycles at 94°C for 15 s and 60°C for 1 min. Melting 
curve analysis was performed at the end of each PCR assay as a control for specificity. Data were 
expressed as Ct values and used for the relative quantification of targets with the ΔΔCt calculation. To 
exclude potential bias due to averaging data transformed through the equation 2−ΔΔCt to give N-fold 
changes in gene expression, all statistics were performed with ΔCt values. 
 
GRIP-STRENGTH ANALYSIS 
Mice were brought to the testing room and allowed to acclimatize for 10 minutes. A Grip Strength 
Meter (Ugo Basile) was used to measure forelimb grip strength. The grip strength meter was 
positioned horizontally, and mice were held by the tail and lowered toward the apparatus. Mice were 
allowed to grasp the smooth metal pull bar with their forelimbs only and then were pulled backward 
in the horizontal plane. The force applied to the bar at the moment of grasping release was recorded 
as the peak tension (grams). The test was performed weekly, repeated five consecutive times within 
the same session, discarding the highest and the lowest values from the five trials and recording the 
mean value of the three remaining measurements. 
 
ROTAROD ANALYSIS 
The rotarod test is one of the oldest used in assessing the effects of a drug on animal behavior. It 
provides a rapid and simple first estimation of any effect on neuromuscular coordination. The rotarod 
consists of a circular rod turning at a constant or increasing speed. Animals placed on the rotating rod 
try to remain on it rather than fall onto a platform 15 cm below. This test is easily automated with 
several animals being tested simultaneously on the same rod. Vertical barriers are used to separate 
the animals from one to another. Locomotor coordination on the rotarod is not a measure of muscle 
strength but an initial screen for neuromuscular impairment. 
Two trials were performed weekly using the Ugo Basile ROTA-ROD for mice (Ugo Basile). Mice were 
put on the rod at speed of 30 rpm for a maximum period of 600 s, and the best performance for each 
mouse was recorded 
 
HISTOLOGICAL ANALYSIS 
Tissues (seminal vesicle and muscle) were collected immediately after euthanasia, muscle were flash-
frozen in isopentane precooled, and stored at − 80 °C until further processing. Frozen muscles were 
embedded in optimal cutting temperature (OCT) compound (Tissue Tek, Sakura, Torrance, CA), and 
cross sections (40 μm thick) were cut with a cryostat (CM1850 UV, Leica Microsystem, Wetzlar, 
Germany). Cryosections of quadriceps were stained for hematoxylin and eosin (H&E). For hematoxylin 
and eosin staining, sections were air-dried and incubated in hematoxylin (Sigma-Aldrich) for 3 
minutes, then washed in water and incubated in eosin (Roth, Karlsruhe, Germany) for 1 minute. After 
incubation, sections were washed in water and dehydrated rapidly in 70, 80 and 100% ethanol, and 
xylene. Sections were mounted with di-Nbutyle phthalate in xylene (DPX) mounting media (Sigma-
Aldrich). Images were taken using a Nikon Eclipse 90i upright microscope and analyzed by 
Neurolucida® software (mbf-bioscience). 
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MASS SPECTROMETRY ANALYSIS 
HPLC operating conditions (Trehalose) 
A Shimadzu (Shimadzu, Koyoto, Japan) SIL series LC system equipped with degasser (DGU‐20A3), 
isopump (LC‐20AD) and column oven (CTO‐10AS) along with an auto‐sampler (SIL‐HTc) was used to 
inject 10 μL aliquots of the processed samples on an ACQUITY UPLC BEH AMIDE column (100 × 2,1 
mm, 3,5 µm; Waters, Dublin, Ireland, UK), which was maintained at 35 ± 1°C. An isocratic mobile phase 
comprising 0.1% ammonium hydroxide, 25% H20, 74,9% acid–acetonitrile (35:65, v/v) delivered at a 
flow‐rate of 0.3 mL/min was used for chromatographic resolution of trehalose and IS. 
HPLC operating conditions (Bicalutamide) 
A Shimadzu (Shimadzu, Koyoto, Japan) SIL series LC system equipped with degasser (DGU‐20A3), 
isopump (LC‐20AD) and column oven (CTO‐10AS) along with an auto‐sampler (SIL‐HTc) was used to 
inject 2 μL aliquots of the processed samples on an Atlantis dC18 column (50 × 4.6 mm, 3 µm; Waters, 
Dublin, Ireland, UK), which was maintained at 40 ± 1°C. An isocratic mobile phase comprising 0.2% 
formic acid–acetonitrile (35:65, v/v) delivered at a flow‐rate of 0.5 mL/min was used for 
chromatographic resolution of bicalutamide and IS. 
Mass spectrometry operating condition  
Quantitation was achieved by MS/MS detection in negative ion mode for bicalutamide and trehalose 
and IS using an MDS Sciex (Foster City, CA, USA) API‐4000 mass spectrometer, equipped with a 
Turboionspray™ interface at 500°C. The common parameters, viz. curtain gas, GS1 gas and GS2 gas, 
were set at 20, 35 and 45 L/min, respectively, whereas the CAD gas was set at 6.0 L/min. The 
compound parameters, viz. de-clustering potential, enhanced potential, collision energy and collision 
exit potential, for bicalutamide and IS were: −45, −10, −22, −13 V and −55, −10, −26, −15 V, 
respectively. Detection of the ions was performed in the multiple reaction monitoring (MRM) mode, 
monitoring the transition of the m/z 429.8 precursor ion to the m/z 254.7 product ion for bicalutamide 
and m/z 269.0 precursor ion to the m/z 169.6 product ion for IS. M/z 316, 119 m/z and 88,8 for 
trehalose. Quadrupole Q1 and Q3 were set on unit resolution. The analytical data were processed 
using Analyst software. 
 
Sample preparation and calibration curves 
A simple protein precipitation method was utilized for extraction of bicalutamide from mouse plasma. 
To an aliquot of 50 μL plasma sample or spinal cord lysate (obtained by homogenizing 15mg of tissue 
with TissueLyser system (Quiagen)), 200 μL of precipitation solution (i.e. acetonitrile with 100 ng/mL 
IS) was added, and the mix vortexed for 15 s on a cyclo mixer (Remi Instruments, Mumbai, India). Then 
samples were centrifuged at 14,000 rpm for 10 and clear supernatant (2 μL or 10 μL) was injected 
onto the LC‐MS/MS system for analysis. 
The point calibration curve (0-10-50-100-150-200 ng/10μL trehalose or 0-10-100 ng/10μL) was 
constructed by plotting the peak area ratio of compound–IS against the nominal concentration of 
compound standards in control mouse plasma or tissue lysate. Following the evaluation of different 
weighting factors, the results were fitted to linear regression analysis with the use of a 
1/x2 (x = concentration) weighting factor. The calibration curve had to have a correlation coefficient 
(r) of 0.99 or better. 
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STATISTICAL ANALYSIS 
Statistical analysis was performed through two-tailed Student t-test for comparisons between two 
groups (Control vs. axotomized, NTg vs. SBMA), one way analysis of variance (ANOVA) followed by 
Tukey post-hoc test for group comparison (pcDNA3 vs. wt-SOD1 and G93A-SOD1), two-way ANOVA 
for group comparisons followed by Bonferroni post-hoc test to determine speciﬁc group pair(s) 
statistical difference and the survival length were statistically evaluated by the Log-rank test to 
compare probabilities using the PRISM software (GraphPad, San Diego, CA, USA). 
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